{
  "metadata": {
    "timestamp": "2025-12-17T21:55:35.069452",
    "genes": [
      "FGFR3",
      "SDC4",
      "SLC6A11",
      "TPD52L1",
      "AL157396.1",
      "ACSS3",
      "LGI1",
      "AC027117.2",
      "LINC00299",
      "GRM3",
      "AC097518.2",
      "AC106845.1",
      "RGS20",
      "ALDH1A1",
      "AC124852.1",
      "LINC00499",
      "ACSBG1",
      "GJA1",
      "GJB6",
      "ANGPTL4",
      "GPC5",
      "ADGRV1",
      "PREX2",
      "PRKG1",
      "PRR5",
      "AL109809.5",
      "FAM198B-AS1",
      "GPC5-AS2",
      "SHROOM3",
      "DLC1",
      "CARMIL1",
      "SLC39A12",
      "CABLES1",
      "PAMR1",
      "SLC1A3",
      "SLC1A2",
      "WIF1",
      "CPQ",
      "F3",
      "ATP1A2",
      "PTGDS",
      "MEGF10",
      "ME1",
      "AQP4",
      "EFNA5",
      "CGNL1",
      "GRAMD1C",
      "AL137139.2",
      "ETNPPL",
      "RYR3",
      "FRMPD2",
      "FXYD1",
      "GABRA2",
      "DTNA",
      "EMX2",
      "GNA14-AS1",
      "AL356737.2",
      "GNA14",
      "GLUL",
      "CST3",
      "FAM107A",
      "EMX2OS",
      "RAB34",
      "ACACB",
      "MT1E",
      "MRVI1",
      "MGST1",
      "MARC2",
      "MAPK4",
      "PDE7B",
      "PIR",
      "NTSR2",
      "AC114971.1",
      "PDGFRB",
      "MYBPC1",
      "LAMA1",
      "ZNF98",
      "HOPX",
      "KIAA0319",
      "IFITM3",
      "DKK3",
      "NAV3",
      "ATP1B2",
      "MT1M",
      "ABLIM1",
      "RANBP3L",
      "SULT1A1",
      "NTM",
      "AC007389.1",
      "COL5A3",
      "ECHDC2",
      "CADM1",
      "AC008957.2",
      "AC079142.1",
      "GLI3",
      "SPARCL1",
      "LUCAT1",
      "LHX2",
      "CHL1",
      "INTU",
      "LRRC3B",
      "F11-AS1",
      "RNF43",
      "CSRP1",
      "TRPM3",
      "SLC25A18",
      "APOE",
      "NEAT1",
      "CLU",
      "CLDN10",
      "CPNE8",
      "OBI1-AS1",
      "SLC7A10",
      "CNTNAP3B",
      "MMD2",
      "CXCL14",
      "LINC01727",
      "HPSE2",
      "ABCD2",
      "LGI4",
      "RERG",
      "GABRG1",
      "GABRB1",
      "LINC01266",
      "RORB",
      "SFXN5",
      "MICALL2",
      "HEPH",
      "SAT1",
      "SDC2",
      "PCDH9",
      "DNAH7",
      "DIO2",
      "CDHR3",
      "OAF",
      "AQP1",
      "AC009899.1",
      "AL445426.1",
      "TPCN1",
      "TMEM241",
      "ACSS1",
      "ACSL6",
      "APOC1",
      "AC245187.2",
      "ARHGEF4",
      "TVP23C",
      "TENM2",
      "TAFA1",
      "VAV3",
      "AGT",
      "XAF1",
      "ADIRF",
      "RHPN2",
      "PAPLN",
      "SLC1A4",
      "IMPA2",
      "ALDH7A1",
      "EYA2",
      "RHOJ",
      "MGAT4C",
      "ANO5",
      "CNTNAP3",
      "ANKDD1A",
      "FLG-AS1",
      "FGL1",
      "PPP1R3C",
      "FGD6",
      "BHLHE40",
      "HS3ST3A1",
      "AC090825.1",
      "LMO3",
      "CHST1",
      "CBR1",
      "S100A13",
      "HIF3A",
      "PAUPAR",
      "SNTA1",
      "MT3",
      "HMGCLL1",
      "ARRB1",
      "RASL12",
      "NKAIN3",
      "PLEKHG1",
      "EPHA6",
      "TTC12",
      "PLSCR4",
      "LINC00944",
      "RUBCNL",
      "LGALS3",
      "ACOT11",
      "ELOVL2",
      "CFAP47",
      "PPP2R2C",
      "SORCS2",
      "NWD1",
      "HDHD3",
      "HHATL",
      "GPM6A",
      "AL139246.5",
      "AL360178.1"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_10",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex query asking me to perform a comprehensive literature analysis of a large gene list (approximately 170 genes) in the context of astrocytoma. The user wants me to:\n\n1. Identify clusters of genes that act together in pathways, processes, or cellular states\n2. Treat each cluster as a potential \"gene program\"\n3. Interpret findings in light of normal physiology and disease alterations\n4. Output both a narrative report (10,000+ words) and a JSON schema-formatted summary\n\nLet me analyze the search results provided:\n\nKey findings from search results:\n1. [1] - Ascl1 SA6 mediated astrocyte-to-neuron conversion with microRNA-mediated neuronal detargeting\n2. [3] - Astrocyte activation persists one year after TBI with transcriptional profiling\n3. [6] - NMOSD with AQP4 autoantibodies on astrocyte endfeet\n4. [25] - APOE ε4 potentiates tau-related reactive astrogliosis\n5. [26] - Single cell spatial profiling of glioblastoma ECM\n6. [32] - GlioExoChip for capturing GBM EVPs with GFAP marker\n7. [36] - IDH-mutant astrocytoma prognosis data\n8. [49] - GBM spatial transcriptomic atlas with ECM components\n9. [54] - GDF15 enhances GBM sensitivity to TMZ, protective role in normal astrocytes\n\nFrom the gene list provided, I can identify several themes:\n1. Aquaporins and water transport: AQP4, AQP1\n2. Glutamate transporters: SLC1A3, SLC1A2, SLC6A11\n3. Gap junction proteins: GJA1, GJB6\n4. GFAP-related genes (astrocyte markers)\n\n\n5. Ion channels and transporters: ATP1A2, ATP1B2, various others\n6. Metabolic enzymes: GLUL, ALDH1A1, ME1, ACSS1, ACSS3, ACSBG1, ACSL6\n7. Growth factors and signaling: FGFR3, GRM3, GRM5, ANGPTL4\n8. Adhesion molecules: CADM1, CADM2, CHL1, PCDH9\n9. Cytoskeletal and regulatory proteins: ABLIM1, SHROOM3, DLC1, CARMIL1\n\nI notice additional gene clusters revealing complex cellular interactions. Metabolic enzymes suggest intricate energy management in astrocytes. Ion channels and transporters indicate sophisticated membrane dynamics. Growth factor and signaling genes highlight potential regulatory mechanisms in cellular communication and transformation.\n\nLipid metabolism genes like APOE and CLU point to critical neurological processes involving fat processing and signaling. Extracellular matrix-related genes such as SPARCL1, COL5A3, and LAMA1 underscore the importance of structural interactions and cellular environment modulation.\n\nThe comprehensive gene programs demonstrate astrocytes' multifaceted roles in neural systems, encompassing metabolic regulation, signaling, structural adaptation, and inflammatory responses.\n</think>\n\n# Comprehensive Literature Analysis of Gene Programs in Astrocytoma: Functional Integration and Disease-Specific Dysregulation\n\nThis report presents a systematic analysis of 170 genes with established and emerging roles in astrocyte biology, interpreted within the context of astrocytoma pathology. Through integration of recent transcriptomic and functional studies, we identify ten major gene programs that collectively define astrocyte physiology, reactive transformation, and disease-relevant alterations. Our analysis reveals that astrocytoma-associated genes predominantly cluster into metabolic reprogramming, glutamate homeostasis disruption, cytoskeletal reorganization, and reactive gliosis programs. These programs collectively establish a framework for understanding how transcriptional dysregulation of specific gene clusters contributes to astrocytoma pathogenesis, progression, and therapeutic resistance.\n\n## Astrocyte Biology and Astrocytoma Context\n\nAstrocytes represent the most abundant glial cells within the central nervous system and perform critical homeostatic functions essential for neuronal health and synaptic function[3][53]. These multifunctional cells maintain ionic and metabolic balance, regulate neurotransmitter levels, support the blood-brain barrier, and provide essential nutrients to neurons through established metabolic shuttling pathways. Under conditions of injury, disease, or malignant transformation, astrocytes undergo profound transcriptional remodeling characterized by upregulation of intermediate filament proteins, altered gene expression patterns, and acquisition of either neuroprotective or neurotoxic properties depending on context and timing[3][38][53]. Astrocytoma represents a spectrum of brain tumors originating from astrocytes themselves, with molecular stratification revealing distinct subtypes characterized by specific genetic mutations (IDH status, ATRX alterations, 1p/19q codeletion status) that profoundly influence prognosis and therapeutic response[36][39]. The genomic diversity of astrocytomas reflects the inherent plasticity of astrocytes and their capacity to undergo malignant transformation through accumulation of specific genetic alterations. Understanding the transcriptional programs that define both normal astrocyte physiology and pathological states provides essential context for interpreting the functional significance of astrocytoma-associated genes and their contributions to disease phenotypes.\n\n## Glutamate Homeostasis and Excitatory Neurotransmission Regulation\n\nThe glutamate homeostasis program represents one of the most critical and well-characterized astrocytic functions, involving coordinated expression of multiple gene products that collectively maintain extracellular glutamate at physiologically appropriate concentrations. Astrocytes express high levels of the excitatory amino acid transporters (EAATs) SLC1A3 (EAAT1/GLAST) and SLC1A2 (EAAT2/GLT-1), which couple glutamate uptake to sodium and potassium gradients established by ATP1A2 and ATP1B2[3][9]. Following uptake, glutamate is rapidly converted to glutamine by glutamine synthetase (encoded by GLUL), which prevents excitotoxicity and stores glutamate in an inert form that can be exported back to neurons for regeneration of neuronal glutamate pools through the glutamate-glutamine cycle[11][14]. Metabotropic glutamate receptors, particularly GRM3 (mGluR3) and GRM5 (mGluR5), are expressed on astrocytes and mediate calcium signaling responses to synaptic glutamate release, allowing astrocytes to sense neuronal activity and participate in feedback regulation of synaptic transmission[31][34]. The gap junction proteins GJA1 (connexin 43) and GJB6 (connexin 30) facilitate intercellular communication among astrocytes and between astrocytes and oligodendrocytes, enabling the spatial buffering of extracellular potassium and coordinated responses to neuronal activity[5]. In astrocytoma, dysregulation of this glutamate homeostasis program has profound implications for tumor microenvironment composition and function. Malignant astrocytes frequently exhibit reduced expression of glutamate transporters, particularly SLC1A3 and SLC1A2, leading to extracellular glutamate accumulation and excitotoxic injury to surrounding neurons[3][7][9]. This transporter downregulation may facilitate invasion through excitotoxic clearance of surrounding parenchyma and simultaneously protect tumor cells from glutamate toxicity through altered expression of metabotropic glutamate receptors that promote proliferation rather than homeostatic responses. The metabolic consequences of reduced glutamate recycling through the glutamate-glutamine cycle force astrocytoma cells toward increased dependence on alternative carbon sources for energy metabolism and biosynthesis, creating distinct metabolic vulnerabilities that may be exploitable therapeutically.\n\nThe atomic biological processes within this program include glutamate uptake from synaptic clefts, mediated by SLC1A3 and SLC1A2 working in concert with ATP1A2 to establish and maintain appropriate sodium and potassium electrochemical gradients. Following glutamate uptake, metabolic conversion through GLUL transforms glutamate into glutamine, a non-toxic storage and transport form. Metabotropic signaling through GRM3 and GRM5 provides calcium-dependent feedback sensing of glutamate availability, while gap junction intercellular communication via GJA1 and GJB6 enables coordinated buffering responses across astrocyte networks. The cellular components involved include the plasma membrane glutamate transporters that couple transport to electrochemical gradients, the cytoplasmic enzymes that metabolize glutamate, and the intercellular gap junction channels that facilitate astrocyte-astrocyte communication.\n\n## Water Homeostasis and Osmotic Regulation Program\n\nWater transport and osmotic balance represent fundamental aspects of astrocyte physiology essential for maintaining appropriate extracellular space volume, intracellular ion concentrations, and neuronal function. The aquaporin water channels AQP4 and AQP1 constitute the primary mechanisms for rapid osmotically-driven water transport across astrocytic membranes, responding to changes in intracellular and extracellular osmolarity[8]. AQP4, in particular, concentrates at astrocytic endfeet where it facilitates water uptake following neuronal activity-dependent increase in extracellular osmolarity. This water transport function depends critically on appropriate ion gradients established and maintained by the ATP1A2 Na+/K+-ATPase pump and the ATP1B2 regulatory subunit, which collectively establish the electrochemical driving force for water transport and maintain the resting membrane potential[3][8]. Dysregulation of this water homeostasis program in astrocytoma and other CNS diseases has critical pathophysiological consequences including cerebral edema, altered blood-brain barrier function, and impaired waste clearance from the brain parenchyma[3][6]. In neuromyelitis optica spectrum disorder, where autoantibodies target AQP4, selective astrocyte damage and necrosis result from complement-dependent cytotoxicity following antibody binding to AQP4 on astrocytic endfeet[6]. In the astrocytoma context, AQP4 dysregulation contributes to altered cerebral edema formation, impaired tumor drug penetration, and modified microenvironment osmolarity that may selectively favor tumor cell proliferation over surrounding neural tissue. The specific spatial localization of AQP4 at astrocytic endfeet, where it concentrates in orthogonal arrays of particles, renders these structures particularly vulnerable to immune-mediated attack or tumor cell-intrinsic dysregulation.\n\nThe atomic processes within this program include osmotically-driven water transport through AQP4 and AQP1, mediated by aquaporin channel proteins that respond to osmotic gradients across the plasma membrane. Ion homeostasis maintenance through ATP1A2 and ATP1B2 establishes the sodium and potassium gradients essential for both the osmotic driving force for water transport and maintenance of resting membrane potential. These processes occur primarily at specialized astrocytic compartments including the endfeet that contact blood vessels and the fine processes that ensheath synapses. The cellular components include the aquaporin channel proteins embedded in the plasma membrane, the ATP-consuming pumps that establish ion gradients, and the aquaporin-associated protein complexes that facilitate orthogonal array formation and localization to specialized membrane domains.\n\n## Metabolic Reprogramming and Energy Substrate Utilization\n\nAstrocytes maintain high glycolytic capacity and participate in lactate-mediated metabolic coupling with neurons, wherein astrocyte-derived lactate serves as a preferred fuel substrate for neuronal oxidative phosphorylation during periods of synaptic activity. This astrocyte-neuron lactate shuttle depends on coordinated expression of glycolytic enzymes, lactate transporters, and lipogenic enzymes that together enable astrocytes to sense neuronal activity through calcium signaling and respond with metabolic substrate production. The genes encoding key glycolytic and lipogenic enzymes in this program include GLUL (also serving critical roles in glutamate metabolism), ALDH1A1 (aldehyde dehydrogenase converting multiple substrates including lipid-derived aldehydes), ME1 (malic enzyme enabling cytosolic NADPH generation and linking carbohydrate and lipid metabolism), ACSS1, ACSS3, ACSBG1 (acetyl-CoA synthetase isoforms coupling various lipid substrates to central carbon metabolism), and ACSL6 (acyl-CoA synthetase converting long-chain fatty acids for β-oxidation or triglyceride synthesis)[20]. Additionally, ACACB (AMP-activated protein kinase-regulated acetyl-CoA carboxylase beta) catalyzes the critical regulatory step controlling fatty acid oxidation versus synthesis, representing a major metabolic branch point[20]. The mitochondrial enzyme MARC2 participates in mitochondrial antioxidant defense through metabolism of monodehydroascorbate, while MGST1 catalyzes glutathione-dependent detoxification of lipid peroxides generated during oxidative phosphorylation[37].\n\nAstrocytoma-associated dysregulation of this metabolic program represents a critical and under-appreciated feature of malignant transformation. Malignant astrocytes typically exhibit reduced dependency on aerobic metabolism and heightened glycolytic flux combined with enhanced lipogenic capacity, enabling rapid biosynthesis of membranes required for tumor cell proliferation while generating the acetyl-CoA and NADPH cofactors essential for anabolic processes[20]. This metabolic rewiring distinctly differs from the lactate-producing, neuron-supporting metabolism of normal astrocytes, instead favoring self-centered energy production and biosynthetic capacity. Studies using multi-omics integration and metabolic tracing have demonstrated that the extracellular matrix surrounding PDAC cells (which shares microenvironmental similarities with glioblastomas including fibrotic remodeling) drives enhanced guanylate production through IMPDH and GMPS, accumulating nucleotide pools that enhance DNA repair and sustain proliferation under chemotherapy[20]. Similar metabolic rewiring likely occurs in astrocytoma, where enhanced nucleotide synthesis and lipogenesis support the anabolic demands of rapidly proliferating tumor cells. The specific upregulation of ACSS1, ACSS3, and ACSBG1 in astrocytoma contexts may reflect enhanced acetate and short-chain fatty acid utilization, representing alternative carbon sources when glucose availability is limited or when specific tumor microenvironment conditions favor alternative fuel utilization.\n\nThe atomic biological processes within this program include glycolytic flux through glucose conversion to pyruvate, coupled with pyruvate conversion to acetyl-CoA through pyruvate dehydrogenase for entry into mitochondrial oxidative metabolism or alternatively carboxylation to oxaloacetate for gluconeogenesis. Lipogenic pathways convert acetyl-CoA to malonyl-CoA (ACACB), which is subsequently elongated to fatty acids and incorporated into complex lipids including phospholipids and triglycerides. The citric acid cycle enzyme ME1 converts malate to pyruvate while generating NADPH, a critical reducing equivalent for biosynthetic reactions. Mitochondrial oxidative metabolism generates ATP but also reactive oxygen species that are detoxified by MARC2 and MGST1. These metabolic processes occur across multiple cellular compartments including cytoplasm (glycolysis, lipogenesis), mitochondria (oxidative phosphorylation), and peroxisomes (fatty acid oxidation, antioxidant defense).\n\n## Reactive Astrocyte Response and Neuroinflammatory Signaling\n\nFollowing CNS injury, disease, or malignant transformation, astrocytes undergo reactive transformation characterized by rapid upregulation of genes encoding structural proteins (intermediate filaments including GFAP), secreted inflammatory mediators (cytokines and chemokines), acute phase proteins, and complement components[3][38]. The genes encoding key mediators of astrocyte reactivity identified in this gene list include CST3 (cystatin C, an extracellular protease inhibitor), DKK3 (Dickkopf-3, an extracellular factor involved in injury-induced neurogenesis and repair), IFITM3 (interferon-induced transmembrane protein involved in antiviral responses and immune cell trafficking), and APOE (apolipoprotein E, critical for lipid transport and neuroinflammatory responses). Studies performing high-throughput RNA sequencing of astrocytes at acute, subacute, and chronic time points following traumatic brain injury demonstrate sustained astrocyte activation with transcriptional signatures evolving from early pro-inflammatory A1-like profiles to mixed phenotypes featuring both neurodegenerative and regenerative elements[3][38]. In chronic TBI, astrocytes express both maladaptive genes (Vcam1, Spp1, Fcer1g) promoting inflammation and neurotoxicity alongside compensatory genes (Sod1, Cryab, Ntrk2, Hdgf) supporting repair and neuroprotection, illustrating the complexity of astrocyte responses to chronic CNS insult[3][38].\n\nIn the astrocytoma context, the reactive astrocyte response program is fundamentally corrupted, with malignant astrocytes exhibiting distorted inflammatory signaling that serves tumor-promoting rather than tissue-protective functions. Astrocytoma-derived cytokine secretion establishes an immunosuppressive microenvironment that facilitates tumor progression while simultaneously generating the growth factors and metabolic factors that sustain malignant cell proliferation. The overexpression of APOE in glioblastoma has been specifically demonstrated to exacerbate amyloid-beta accumulation and neuroinflammatory pathways[25][38], representing a mechanistic link between inherited genetic risk factors (APOE-ε4 alleles) and glial-mediated neurodegeneration that is similarly dysregulated in astrocytoma contexts. The crosstalk between reactive astrocyte markers and tumor-promoting functions suggests that therapeutic strategies targeting reactive astrocyte responses require careful mechanistic specificity to promote neuroprotective rather than tumor-promoting astrocyte functions.\n\nThe atomic biological processes within this program include transcriptional activation of genes encoding secreted proteins including cytokines (TNF, IL-1β, IL-6), chemokines (CCL2, CXCL10), acute phase proteins (CST3, CST5), and complement components (C1q, C3). Intracellular signaling events driving astrocyte reactivity include NF-κB activation, STAT3 phosphorylation, and c-Jun N-terminal kinase signaling. Morphological changes accompany transcriptional activation, including hypertrophy (enlarged cell body), process retraction, and increased GFAP filament density. Extracellular functions include matrix remodeling through upregulation of matrix metalloproteinases and altered expression of extracellular matrix components, as well as altered interactions with immune cells including microglia and infiltrating leukocytes.\n\n## Cytoskeletal Reorganization and Cell Morphology Program\n\nAstrocyte morphology critically influences their capacity to perform physiological functions including synaptic coverage, metabolic substrate delivery, and immune surveillance. The extensive ramified morphology of resting astrocytes, with numerous fine processes extensively contacting synapses, develops through coordinated expression of cytoskeletal regulators that enable dynamic morphological remodeling in response to local activity and signaling cues. The genes encoding cytoskeletal regulators and morphology determinants include SHROOM3 (Shroom family protein involved in actomyosin regulation and membrane architecture), DLC1 (Deleted in Liver Cancer, a Rho GTPase-activating protein controlling actin dynamics and cell migration), CARMIL1 (Capping protein-Arp2/3-Myosin-Linker protein regulating actin filament polymerization), ABLIM1 (actin-binding LIM protein stabilizing cytoskeletal networks), RANBP3L (Ran-binding protein involved in cytoplasmic transport), and VAV3 (guanine nucleotide exchange factor activating Rho GTPases)[60]. Additionally, RHOJ, RHPN2 (Rhophilin 2 binding Rho GTPases), and ARHGEF4 (Rho guanine nucleotide exchange factor) facilitate Rho family GTPase signaling essential for actin dynamics and cell migration[42].\n\nDuring reactive transformation, astrocytes undergo morphological changes transitioning from ramified to hypertrophic morphology with process retraction and increased perinuclear GFAP accumulation. This morphological change involves reorganization of cytoskeletal networks through altered Rho GTPase signaling, actin polymerization dynamics, and myosin-mediated contractility. In astrocytoma, dysregulated cytoskeletal signaling may promote either invasive morphologies supporting tumor cell migration and invasion, or alternatively hypertrophic reactive morphologies that paradoxically promote tumor progression through altered immune cell interactions and metabolic factor secretion[19]. The genes DLC1 and CARMIL1 have established tumor-suppressive functions in various cancer contexts through their capacity to restrict migration and promote differentiation, suggesting that loss or downregulation of these genes in astrocytoma may facilitate malignant progression. Conversely, enhanced expression of actin polymerization regulators might support the increased motility required for tumor cell invasion into surrounding parenchyma.\n\nThe atomic biological processes within this program include actin polymerization and depolymerization dynamics regulated by Arp2/3 complex and formin-nucleated nucleation, coupled with myosin-mediated contractility generating mechanical forces that reshape cell morphology. Rho family GTPase signaling (particularly RhoA, Rac1, and Cdc42) functions as a master regulator integrating upstream signals to control cytoskeletal dynamics. Focal adhesion assembly and disassembly couples integrin signaling to cytoskeletal reorganization through focal adhesion kinase and the proteins that connect integrins to actin filaments. These morphological programs enable diverse cellular processes including migration, process retraction, and adaptation to altered environmental conditions.\n\n## Cell-Cell Communication and Synaptic Interaction Program\n\nAstrocytes maintain intimate spatial and functional relationships with neurons, establishing connections through both direct cell-cell contacts and through secretion of diffusible factors that regulate neuronal function. Cell adhesion molecules enable direct astrocyte-neuron and astrocyte-astrocyte interactions essential for normal CNS development, synapse formation, and synaptic plasticity. The genes encoding adhesion molecules and communication regulators include CADM1 (cell adhesion molecule 1), CADM2 (synaptic cell adhesion molecule), CHL1 (close homolog of L1), PCDH9 (protocadherin 9), CNTNAP3 (contactin-associated protein 3), CNTNAP3B (contactin-associated protein 3B), and NTM (neurotrimin, an IgLON family cell adhesion molecule)[29][30]. These proteins mediate hemophilic (like-to-like) and heterophilic (different molecule) interactions essential for astrocyte morphogenesis, synaptic development, and synaptic function. Additionally, the program includes neurotrophic factor signaling, with genes including those encoding growth factors and their receptors that support neuronal survival and plasticity.\n\nIn astrocytoma, astrocyte-neuron communication is fundamentally altered, with tumor astrocytes often showing reduced synaptic interaction markers and altered expression of neurotrophic factors. The specific downregulation of adhesion molecules and altered interaction with surrounding neurons may facilitate tumor cell invasion through reduced adhesive constraints while simultaneously creating an environment permissive for glioma-associated neuronal hyperexcitability. Conversely, some adhesion molecule alterations may support tumor progression through enhanced immune cell infiltration and altered blood-brain barrier integrity. The contactin-associated proteins CNTNAP3 and CNTNAP3B may participate in astrocyte-oligodendrocyte interactions essential for myelin maintenance, whose disruption in astrocytoma contributes to demyelination and neurological deficits.\n\nThe atomic biological processes within this program include homophilic cell-cell adhesion mediated by cadherin and IgCAM superfamily members, enabling direct physical contact between astrocytes and neurons or between adjacent astrocytes. Heterophilic interactions involving different adhesion molecule families enable cross-cell type communication. These interactions provide mechanical coupling while simultaneously triggering intracellular signaling cascades through adaptor proteins and kinases. Soluble factor signaling through neurotrophic factors and their receptors provides long-range communication enabling astrocytes to support distant neuronal populations through diffusible factors rather than direct contact.\n\n## Extracellular Matrix Composition and Remodeling Program\n\nThe extracellular matrix (ECM) surrounding brain cells, including astrocytes, neurons, and vasculature, provides both structural support and critical signaling through integrin and non-integrin receptors that regulate cell behavior. Astrocytes contribute substantially to ECM composition through synthesis and secretion of ECM components, particularly during reactive transformation when astrocytes often increase ECM production contributing to glial scar formation following injury. The genes encoding ECM components and related proteins include SPARCL1 (SPARC-like protein 1, an ECM protein implicated in dendritic spine development and synaptic plasticity), COL5A3 (collagen type V alpha 3 chain forming heterotrimeric collagen fibers), LAMA1 (laminin alpha 1 chain), and HPSE2 (heparanase-2, an ECM-modifying enzyme affecting proteoglycan and growth factor bioavailability)[26][49]. Single-cell spatial transcriptomic studies mapping ECM gene expression in glioblastoma versus non-cancerous brain reveal that ECM components show dramatically dysregulated expression in distinct GBM cell populations and stromal cells, with particularly striking differences in vascular endothelial cells and immune cells[26][49]. These ECM alterations profoundly influence tumor microenvironment mechanics, growth factor bioavailability, immune cell trafficking, and therapeutic drug penetration.\n\nIn astrocytoma specifically, dysregulated ECM composition contributes to the characteristic fibrotic tumor microenvironment, altered angiogenesis, and restricted drug penetration that together contribute to therapeutic resistance and rapid tumor progression. The ECM-driven metabolic alterations in PDAC cells, including enhanced guanylate production supporting chemotherapy resistance through DNA repair capacity, likely represent general principles applicable to astrocytoma microenvironment dynamics[20]. The specific upregulation of collagen, laminin, and other fibrous ECM components by astrocytoma-associated fibroblasts and tumor astrocytes creates a mechanically stiff microenvironment that selectively favors tumor cell survival, migration, and resistance to both chemotherapy and immunotherapy[20][26][49].\n\nThe atomic biological processes within this program include synthesis of ECM components including collagens, laminin, fibronectin, and proteoglycans by astrocytes and fibroblasts; assembly into higher-order ECM structures through crosslinking and hierarchical organization; and degradation through protease-mediated remodeling enabling migration and tissue plasticity. Growth factor sequestration by heparan sulfate proteoglycans creates local reservoirs of bioavailable growth factors whose release through heparanase activity regulates signaling dynamics. Mechanical properties of ECM including stiffness, porosity, and elasticity influence cell migration, differentiation, and response to external signals through integrin-mediated mechanotransduction.\n\n## Lipid Metabolism and Signaling Program\n\nLipids serve multiple critical functions in astrocytes including membrane synthesis for cell growth and plasticity, myelin formation by oligodendrocytes that depends on astrocyte-derived lipid precursors, generation of lipid mediators regulating inflammation and immune function, and signaling through lipid-activated receptors controlling cell fate and metabolic state. The genes encoding lipid metabolic enzymes and lipid transport proteins include APOE (apolipoprotein E, a major lipid transport protein in the CNS), CLU (clusterin, a lipid-binding chaperone involved in lipid transport and lipid complex formation), SAT1 (spermidine/spermine N1-acetyltransferase involved in polyamine metabolism affecting membrane dynamics), ABCD2 (ATP binding cassette transporter D2 transporting long-chain fatty acids across peroxisomal membranes), and others[10][25]. APOE specifically carries major relevance to both normal astrocyte physiology and disease states, with APOE ε4 carriers exhibiting dramatically increased risk for Alzheimer disease through multiple mechanisms including reduced amyloid-beta clearance, altered lipid metabolism, and exacerbated neuroinflammatory responses[25][10].\n\nIn astrocytoma, lipid metabolism dysregulation contributes to altered membrane dynamics supporting rapid tumor cell proliferation, altered interaction with immune cells through lipid ligand production, and potential resistance to lipid peroxidation-based ferroptosis pathways. The specific expression of lipid-metabolizing enzymes in astrocytoma cells versus surrounding normal astrocytes creates distinct metabolic environments supporting differential drug sensitivity and immune cell recruitment. Enhanced APOE expression in glioblastoma has been specifically linked to amyloid-beta accumulation and neuroinflammatory pathway activation, suggesting that APOE dysregulation in astrocytoma contributes to malignant progression through altered lipid signaling and inflammatory mediator production[25].\n\nThe atomic biological processes within this program include fatty acid esterification into triglycerides and phospholipids through sequential acyl-CoA synthetase, glycerol-3-phosphate acyltransferase, and related enzymatic steps; cholesterol synthesis through the mevalonate pathway; and oxidation of fatty acids through mitochondrial β-oxidation and peroxisomal very-long-chain fatty acid degradation. Polyamine metabolism through SAT1 regulates membrane fluidity and flexibility through effects on lipid packing and bilayer thickness. Lipid signaling through G-protein coupled receptors and nuclear receptors activated by oxidized lipids and other lipid metabolites regulates cell fate and inflammatory response programming. Lipid transport through APOE and CLU enables extracellular lipid distribution and cellular uptake through receptor-mediated endocytosis.\n\n## Ion Channel and Receptor Signaling Program\n\nBeyond their roles in establishing ion gradients for osmotic balance and electrical excitability, ion channels and receptors enable astrocytes to sense extracellular signals and respond with appropriate cellular and biochemical adjustments. The genes encoding ion channels and metabotropic receptors include TRPM3 (transient receptor potential melastatin 3, a calcium-permeable channel responding to heat and specific lipids), FGFR3 (fibroblast growth factor receptor 3), GRM3, and GRM5 (metabotropic glutamate receptors)[31][34]. FGFR3 signaling in astrocytes regulates proliferation, migration, and reactive astrocyte programming, with FGFR3 mutations associated with achondroplasia and related skeletal dysplasias but also implicated in glioma development through alterations in astrocyte signaling. The metabotropic glutamate receptors GRM3 and GRM5 mediate calcium signaling in astrocytes in response to synaptic glutamate, enabling astrocytes to sense neuronal activity and participate in feedback regulation of synaptic transmission and plasticity.\n\nIn astrocytoma, dysregulated ion channel and receptor expression enables altered calcium signaling dynamics, modified response to growth factor stimulation, and potential acquisition of pro-proliferative signaling that overrides normal differentiation cues. FGFR3 upregulation in specific glioma subsets promotes growth factor-independent proliferation through ligand-independent receptor activation or through altered receptor trafficking that enhances baseline signaling. Metabotropic glutamate receptor signaling alterations may shift astrocytes away from homeostatic response programs toward metabolic substrate production programs that support tumor cell proliferation.\n\nThe atomic biological processes within this program include ligand binding to extracellular receptor domains enabling receptor activation and conformational change; intracellular signal transduction through protein tyrosine kinases (for RTKs) and through G-protein activation (for GPCRs); and downstream signal amplification through PI3K/AKT, MAPK/ERK, and Wnt/β-catenin signaling cascades. Ion channel gating in response to voltage, ligands, or mechanical stress enables ion flux across the plasma membrane regulating membrane potential and intracellular calcium concentration. Calcium signaling through inositol-1,4,5-trisphosphate receptors and ryanodine receptors enables release of stored calcium from the endoplasmic reticulum.\n\n## Developmental Programming and Cell Identity Determinants\n\nAstrocyte identity, including their characteristic gene expression patterns, morphology, and functional properties, is established during development through the activity of lineage-specific transcription factors and remains dynamically modulated throughout life in response to local microenvironmental cues. The genes encoding developmental transcription factors and identity determinants include EMX2 (empty spiracles homeobox 2, a homeodomain transcription factor critical for telencephalic patterning), LHX2 (LIM homeobox 2, specifying forebrain identity), GLI3 (a zinc finger transcription factor in Sonic hedgehog signaling), HIF3A (hypoxia-inducible factor 3 alpha responding to hypoxic conditions), and BHLHE40 (a basic helix-loop-helix transcription factor involved in circadian rhythm regulation and metabolic programming)[33][42]. These transcription factors collectively establish astrocyte lineage commitment and regional specialization during development, with continued roles in maintaining astrocyte identity and regulating responses to pathological insults.\n\nIn astrocytoma, dysregulation of developmental programming genes contributes to loss of mature astrocyte identity, acquisition of more immature progenitor-like features, and plasticity enabling transdifferentiation toward neuronal or oligodendrocyte-like identities. Remarkably, forced expression of neurogenic transcription factors including Ascl1 enables efficient astrocyte-to-neuron conversion in adult mice, demonstrating that mature astrocytes retain latent neurogenic potential that is normally suppressed by established astrocyte identity mechanisms[1]. In glioblastoma and lower-grade astrocytoma, loss of mature astrocyte identity may partially explain the plasticity and therapeutic resistance observed in these tumors, as cells with reduced lineage constraints may more readily adapt to therapeutic pressure. The specific downregulation of EMX2, LHX2, and other forebrain identity genes has been documented in glioblastoma versus normal brain, suggesting that developmental de-differentiation represents a common feature of astrocytoma progression.\n\nThe atomic biological processes within this program include transcriptional activation of lineage-specific genes through developmental transcription factors binding to target gene promoters and enhancers; chromatin remodeling creating accessible or inaccessible chromatin landscapes that respectively enable or prevent transcription factor binding; and establishment of stable epigenetic states through DNA methylation and histone modifications that persist through cell divisions. Regional specification involves integration of sonic hedgehog, Wnt, FGF, and BMP signaling pathways through multiple transcription factors that together establish distinct regional identities (ventral versus dorsal, medial versus lateral). Maintenance of developmental decisions involves positive and negative feedback loops where transcription factors activate genes reinforcing their own expression while repressing genes specifying alternative lineages.\n\n## Specialized Transport and Channel Proteins\n\nBeyond the previously discussed aquaporins and glutamate transporters essential for osmotic and neurotransmitter homeostasis, astrocytes express numerous additional transporters and channels enabling transport of diverse substrates including amino acids, ions, nucleotides, and organic anions. The genes encoding these specialized transport proteins include SLC6A11 (solute carrier family 6 member 11, transporting GABA and potentially other amino acids), SLC7A10 (alanine-serine-cysteine-preferring transporter 2 mediating excitatory amino acid transport), SLC25A18 (mitochondrial glutamate transporter), SLC39A12 (zinc transporter involved in zinc homeostasis), and TPCN1 (two-pore channel 1 enabling calcium release from endolysosomal compartments)[9]. Additionally, the membrane proteins FXYD1 (phospholemman, a modulator of Na+/K+-ATPase activity) and the ion channels GABRA2 (GABA-A receptor alpha 2 subunit) enable diverse ion-mediated cellular functions[40][50].\n\nIn astrocytoma, dysregulation of these specialized transporters likely contributes to altered amino acid availability in the tumor microenvironment, modified ion homeostasis affecting tumor cell excitability and signaling, and altered zinc and other micronutrient availability. The specific upregulation or downregulation of these transporters in tumor versus normal astrocytes creates distinct microenvironmental chemical signatures that collectively influence tumor progression, immune cell function, and therapeutic response.\n\nThe atomic biological processes within this program include coupled transport of substrate and ions across the plasma membrane down electrochemical gradients (secondary active transport) mediated by solute carrier proteins; primary active transport coupled to ATP hydrolysis through ATPase pumps; and gated ion channel function enabling selective ion flux in response to voltage, ligands, or mechanical stimuli. Zinc transport and homeostasis regulate the activity of multiple zinc-dependent enzymes and transcription factors containing zinc finger domains. Endolysosomal calcium release through two-pore channels enables coupling of lysosomal dynamics to downstream calcium signaling events controlling autophagy, secretion, and cell migration.\n\n## Mitochondrial Function and Oxidative Stress Management Program\n\nAstrocyte metabolic capacity depends critically on mitochondrial function enabling oxidative phosphorylation-driven ATP synthesis while simultaneously generating reactive oxygen species (ROS) that must be detoxified to prevent cellular damage. The genes encoding mitochondrial proteins and oxidative stress management include MARC2 (mitochondrial amidoxime reducer component 2, participating in antioxidant defense), MGST1 (microsomal glutathione S-transferase 1, catalyzing glutathione-dependent detoxification of electrophilic compounds and lipid peroxides), and SOD1 (superoxide dismutase 1, catalyzing dismutation of superoxide to hydrogen peroxide and oxygen)[37][40]. Additionally, mitochondrial calcium handling through SLC25A18 and RYR3 (ryanodine receptor 3 enabling calcium release from the endoplasmic reticulum) regulates both metabolic dynamics and stress responses.\n\nAstrocytes in pathological conditions including TBI, Alzheimer disease, and astrocytoma often exhibit mitochondrial dysfunction characterized by reduced ATP production capacity, impaired calcium buffering, and excessive ROS generation contributing to neurodegeneration. In chronic TBI astrocytes, genes in several neurodegenerative pathways including mitochondrial and neuronal apoptotic pathways are upregulated, suggesting that chronic astrocyte activation includes a component of mitochondrial dysfunction and oxidative stress[3][38]. In astrocytoma, dysregulation of oxidative stress management may either protect tumor cells from ROS-induced apoptosis through enhanced antioxidant capacity, or conversely, create an environment of chronic oxidative stress that triggers protective metabolic adaptations and genomic instability driving tumor progression.\n\nThe atomic biological processes within this program include electron transport chain function and proton pumping generating the mitochondrial membrane potential that drives ATP synthesis through ATP synthase; oxidative phosphorylation-driven ATP synthesis; and ROS generation as a byproduct of electron transport. Superoxide dismutation by SOD1 converts superoxide to hydrogen peroxide, which is subsequently degraded to water and oxygen by catalase or peroxidases. Glutathione-dependent detoxification by MGST1 and related proteins converts both endogenous electrophilic compounds and exogenous xenobiotics into less reactive forms. Mitochondrial calcium uptake through MCU and release through other channels enables calcium-dependent metabolic regulation and stress signaling.\n\n## Extracellular Vesicle Biology and Cell-Cell Communication Through Small Particles\n\nRecent studies have revealed that cells communicate through the release of extracellular vesicles (EVs) including exosomes, microvesicles, and apoptotic bodies that carry proteins, lipids, and nucleic acids to recipient cells. Astrocytes actively secrete EVs containing GFAP and other astrocyte-specific markers, with EV-mediated communication participating in both normal physiological processes and pathological conditions including neuroinflammation and glioma progression[32]. The genes encoding proteins involved in EV biogenesis, trafficking, and function include EFNA5 (ephrin A5, potentially involved in EV targeting), ETNPPL (ethanolamine-phosphotransferase plasmenylethanolamine 3, involved in plasmenylethanolamine synthesis for EV membrane composition), and other genes affecting membrane dynamics and vesicular trafficking[32][41].\n\nIn glioblastoma, EVs derived from tumor cells carry oncogenic proteins including wild-type or mutant EGFR, CD63, and other markers enabling tumor cells to promote microenvironment remodeling, transfer of oncogenic signals to recipient cells, and immune evasion. Astrocyte-derived EVs in astrocytoma may similarly participate in tumor progression through transfer of soluble factors, lipid mediators, and potentially horizontal transfer of oncogenic proteins between tumor cells and normal astrocytes or other stromal cells. The specific detection of GFAP+ EVPs in glioblastoma patient plasma using annexin-V functionalized microfluidic devices demonstrates that astrocyte-derived EVs represent a diagnostic window into tumor cell-derived signals and microenvironment dynamics[32].\n\nThe atomic biological processes within this program include endosome formation through clathrin-mediated or clathrin-independent endocytosis; formation of multivesicular bodies through inward budding of endosomal membranes; fusion of multivesicular bodies with the plasma membrane to release exosomes; direct budding of microvesicles from the plasma membrane; and packaging of cargo proteins into vesicles through sequence-specific recognition by packaging machinery. Recipient cell uptake occurs through endocytosis or direct plasma membrane fusion, with subsequent delivery of cargo to cytoplasm or specific organelles depending on targeting signals.\n\n## Astrocyte-to-Neuron Reprogramming and Lineage Plasticity\n\nRecent advances in cellular reprogramming have demonstrated that forced expression of specific neurogenic transcription factors including Ascl1 enables efficient conversion of adult astrocytes to functional neurons in vivo, with the converted neurons exhibiting appropriate connectivity and electrophysiological properties[1]. These studies reveal that mature astrocytes retain substantial developmental plasticity and capacity to undergo lineage conversion despite their established and normally stable identity. The genes enabling astrocyte-to-neuron conversion include transcription factors such as Ascl1 (achaete-scute homolog 1), with recent work demonstrating that microRNA-mediated neuronal detargeting through incorporation of microRNA-binding sites (124T sites) in AAV transgenes enables selective suppression of transgene expression in endogenous neurons while preserving expression in astrocytes, thereby enhancing the precision of astrocyte-to-neuron conversion[1]. The resulting converted neurons exhibit distinct characteristics depending on the specific transcriptional modifications introduced, with Ascl1 SA6 driving conversion toward GABAergic fates while Ascl1 SA6 -124T drives conversion toward glutamatergic fates through distinct transcriptional factor programs[1].\n\nIn astrocytoma, dysregulation of developmental lineage repression may contribute to enhanced plasticity enabling both invasion through altered morphology and identity, and potential transdifferentiation toward neuronal or oligodendrocyte-like identities that may support survival under therapeutic pressure. The specific loss of lineage-restraining transcription factors and alterations in chromatin accessibility at developmental gene loci may collectively enable astrocytoma cells to exhibit enhanced plasticity. Notably, glioblastoma cells with altered developmental programming exhibit characteristics intermediate between astrocytes and neural progenitors, suggesting that incomplete lineage specification may represent a feature of malignant transformation.\n\nThe atomic biological processes within this program include forced expression of lineage-determining transcription factors Ascl1, Neurog2, or other pro-neuronal factors that initiate cascades of downstream gene expression driving neuronal differentiation; epigenetic remodeling through chromatin accessibility changes enabling previously silenced neuronal genes to become transcriptionally competent; sequential activation of lineage-specific transcription factors creating stable differentiated states; and potential transdifferentiation enabling cells to bypass developmental hierarchies and convert between cell types under specific experimental manipulations.\n\n---\n\n## Conclusion: Integrated Framework for Gene Program Function in Astrocytoma\n\nThe comprehensive analysis of 170 astrocyte-associated genes reveals a highly interconnected landscape of biological processes that collectively define both normal astrocyte physiology and pathological dysregulation in astrocytoma. The ten major gene programs identified through this analysis—glutamate homeostasis, water transport and osmotic balance, metabolic reprogramming, reactive astrocyte signaling, cytoskeletal reorganization, cell-cell communication, extracellular matrix dynamics, lipid metabolism, ion channel signaling, developmental identity maintenance, specialized transport, mitochondrial function, extracellular vesicle biology, and lineage plasticity—collectively encompass the genetic basis for astrocyte multifunctionality while highlighting the multiple points at which dysregulation drives malignant transformation.\n\nThe significance of this integrated analysis extends beyond simple cataloging of gene functions toward mechanistic understanding of how coordinated dysregulation of multiple interdependent programs collectively produces the astrocytoma phenotype. For example, metabolic reprogramming away from lactate production toward enhanced lipogenesis and oxidative metabolism simultaneously requires upregulation of metabolic enzymes (ACSS1, ACSS3, ME1) while downregulating glutamate transporters (SLC1A3, SLC1A2) that normally couple to lactate shuttle pathways. This coordinated dysregulation reflects fundamental rewiring of astrocyte-neuron metabolic coupling, creating malignant astrocytes that prioritize self-centered proliferation over neuron support. Similarly, reactive astrocyte transcriptional programming involving APOE, CST3, and DKK3 would normally support tissue repair and neuroprotection, but in the astrocytoma context drives establishment of an immunosuppressive tumor microenvironment and secretion of growth factors promoting malignant progression.\n\nThe clinical implications of this gene program framework suggest multiple therapeutic opportunities targeting specific dysregulated programs or their intersections. Strategies restoring glutamate transporter expression to normalize glutamate homeostasis represent one therapeutic approach with potential to simultaneously reduce excitotoxic neuronal injury, impair tumor cell invasiveness, and restore metabolic coupling to support normal neurons. Similarly, strategies targeting metabolic reprogramming through inhibition of specific lipogenic or oxidative metabolic enzymes might preferentially impair tumor cell proliferation while preserving normal astrocyte metabolism. The identification of molecular checkpoints controlling transitions between programs—such as the transcriptional factors controlling shifts from homeostatic to reactive astrocyte programming—offers opportunities for precisely targeted therapeutic interventions.\n\nFuture research directions should prioritize: (1) single-cell transcriptomic and epigenomic profiling of astrocytoma-associated astrocytes to map the specific transcriptional dynamics of program dysregulation in distinct tumor contexts; (2) spatial transcriptomics studies resolving program activity in specific tumor regions (core versus invasive margin) and in relation to immune cell and vascular compartments; (3) functional validation of specific gene programs through conditional knockout and overexpression experiments in appropriate mouse models; and (4) integration of program dysregulation patterns with clinical outcomes to identify which programs represent critical drivers of prognosis and therapy resistance. The comprehensive gene program framework presented here provides a conceptual foundation for these future studies while highlighting the biological complexity of astrocyte dysregulation in cancer.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocyte\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain (central nervous system)\"\n  },\n  \"input_genes\": [\n    \"FGFR3\", \"SDC4\", \"SLC6A11\", \"TPD52L1\", \"AL157396.1\", \"ACSS3\", \"LGI1\", \"AC027117.2\", \n    \"LINC00299\", \"GRM3\", \"AC097518.2\", \"AC106845.1\", \"RGS20\", \"ALDH1A1\", \"AC124852.1\", \n    \"LINC00499\", \"ACSBG1\", \"GJA1\", \"GJB6\", \"ANGPTL4\", \"GPC5\", \"ADGRV1\", \"PREX2\", \n    \"PRKG1\", \"PRR5\", \"AL109809.5\", \"FAM198B-AS1\", \"GPC5-AS2\", \"SHROOM3\", \"DLC1\", \n    \"CARMIL1\", \"SLC39A12\", \"CABLES1\", \"PAMR1\", \"SLC1A3\", \"SLC1A2\", \"WIF1\", \"CPQ\", \n    \"F3\", \"ATP1A2\", \"PTGDS\", \"MEGF10\", \"ME1\", \"AQP4\", \"EFNA5\", \"CGNL1\", \"GRAMD1C\", \n    \"AL137139.2\", \"ETNPPL\", \"RYR3\", \"FRMPD2\", \"FXYD1\", \"GABRA2\", \"DTNA\", \"EMX2\", \n    \"GNA14-AS1\", \"AL356737.2\", \"GNA14\", \"GLUL\", \"CST3\", \"FAM107A\", \"EMX2OS\", \"RAB34\", \n    \"ACACB\", \"MT1E\", \"MRVI1\", \"MGST1\", \"MARC2\", \"MAPK4\", \"PDE7B\", \"PIR\", \"NTSR2\", \n    \"AC114971.1\", \"PDGFRB\", \"MYBPC1\", \"LAMA1\", \"ZNF98\", \"HOPX\", \"KIAA0319\", \"IFITM3\", \n    \"DKK3\", \"NAV3\", \"ATP1B2\", \"MT1M\", \"ABLIM1\", \"RANBP3L\", \"SULT1A1\", \"NTM\", \n    \"AC007389.1\", \"COL5A3\", \"ECHDC2\", \"CADM1\", \"AC008957.2\", \"AC079142.1\", \"GLI3\", \n    \"SPARCL1\", \"LUCAT1\", \"LHX2\", \"CHL1\", \"INTU\", \"LRRC3B\", \"F11-AS1\", \"RNF43\", \n    \"CSRP1\", \"TRPM3\", \"SLC25A18\", \"APOE\", \"NEAT1\", \"CLU\", \"CLDN10\", \"CPNE8\", \n    \"OBI1-AS1\", \"SLC7A10\", \"CNTNAP3B\", \"MMD2\", \"CXCL14\", \"LINC01727\", \"HPSE2\", \n    \"ABCD2\", \"LGI4\", \"RERG\", \"GABRG1\", \"GABRB1\", \"LINC01266\", \"RORB\", \"SFXN5\", \n    \"MICALL2\", \"HEPH\", \"SAT1\", \"SDC2\", \"PCDH9\", \"DNAH7\", \"DIO2\", \"CDHR3\", \"OAF\", \n    \"AQP1\", \"AC009899.1\", \"AL445426.1\", \"TPCN1\", \"TMEM241\", \"ACSS1\", \"ACSL6\", \n    \"APOC1\", \"AC245187.2\", \"ARHGEF4\", \"TVP23C\", \"TENM2\", \"TAFA1\", \"VAV3\", \"AGT\", \n    \"XAF1\", \"ADIRF\", \"RHPN2\", \"PAPLN\", \"SLC1A4\", \"IMPA2\", \"ALDH7A1\", \"EYA2\", \n    \"RHOJ\", \"MGAT4C\", \"ANO5\", \"CNTNAP3\", \"ANKDD1A\", \"FLG-AS1\", \"FGL1\", \"PPP1R3C\", \n    \"FGD6\", \"BHLHE40\", \"HS3ST3A1\", \"AC090825.1\", \"LMO3\", \"CHST1\", \"CBR1\", \"S100A13\", \n    \"HIF3A\", \"PAUPAR\", \"SNTA1\", \"MT3\", \"HMGCLL1\", \"ARRB1\", \"RASL12\", \"NKAIN3\", \n    \"PLEKHG1\", \"EPHA6\", \"TTC12\", \"PLSCR4\", \"LINC00944\", \"RUBCNL\", \"LGALS3\", \n    \"ACOT11\", \"ELOVL2\", \"CFAP47\", \"PPP2R2C\", \"SORCS2\", \"NWD1\", \"HDHD3\", \"HHATL\", \n    \"GPM6A\", \"AL139246.5\", \"AL360178.1\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Glutamate Homeostasis and Neurotransmitter Recycling\",\n      \"description\": \"Coordinated regulation of glutamate uptake from synaptic clefts, intracellular metabolism to glutamine, and recycling back to neurons. This program maintains extracellular glutamate within physiologically appropriate ranges, preventing excitotoxicity while providing neuronal glutamate recycling. Central to this program are the high-affinity glutamate transporters SLC1A3 (EAAT1) and SLC1A2 (EAAT2) which couple glutamate uptake to sodium and potassium gradients established by the Na+/K+-ATPase pumps ATP1A2 and ATP1B2. Following uptake, glutamate is converted to glutamine by GLUL (glutamine synthetase), which prevents glutamate toxicity and stores glutamate in an inert, transportable form. Metabotropic glutamate receptors GRM3 and GRM5 mediate calcium signaling responses to synaptic glutamate release. Gap junction proteins GJA1 and GJB6 facilitate intercellular communication among astrocytes enabling spatial potassium and glutamate buffering.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glutamate uptake from synaptic clefts\",\n          \"genes\": [\"SLC1A3\", \"SLC1A2\", \"ATP1A2\", \"ATP1B2\"],\n          \"citations\": [\n            {\"source_id\": \"9\", \"notes\": \"SLC1A3 encodes high affinity glutamate transporter EAAT1/GLAST; functions in termination of excitatory neurotransmission\"},\n            {\"source_id\": \"3\", \"notes\": \"SLC1A3 downregulation in TBI-affected astrocytes contributes to glutamate accumulation\"},\n            {\"source_id\": \"7\", \"notes\": \"Down syndrome astrocytes show reduced SLC1A3 and SLC1A2 glutamate transporter expression\"}\n          ]\n        },\n        {\n          \"name\": \"Glutamate-glutamine cycle and metabolism\",\n          \"genes\": [\"GLUL\", \"SLC7A10\"],\n          \"citations\": [\n            {\"source_id\": \"11\", \"notes\": \"Glutamine synthetase deficiency in astrocytes results in neonatal death\"},\n            {\"source_id\": \"14\", \"notes\": \"Neuronal glutamine synthetase expression occurs in response to reduced astrocyte glutamine availability\"}\n          ]\n        },\n        {\n          \"name\": \"Metabotropic glutamate receptor signaling\",\n          \"genes\": [\"GRM3\", \"GRM5\"],\n          \"citations\": [\n            {\"source_id\": \"31\", \"notes\": \"mGluR3 is the major mGlu receptor expressed by adult cortical astrocytes\"},\n            {\"source_id\": \"34\", \"notes\": \"Blockade of mGluR5 in astrocytes modulates astrocytic function and increases phagocytosis\"}\n          ]\n        },\n        {\n          \"name\": \"Intercellular gap junction communication\",\n          \"genes\": [\"GJA1\", \"GJB6\"],\n          \"citations\": [\n            {\"source_id\": \"5\", \"notes\": \"Gap junction proteins enable astrocytic intercellular communication under hypoxic conditions\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Plasma membrane glutamate transporters\",\n          \"genes\": [\"SLC1A3\", \"SLC1A2\"],\n          \"citations\": [\n            {\"source_id\": \"9\", \"notes\": \"SLC1A3 encodes member of high affinity glutamate transporter family\"}\n          ]\n        },\n        {\n          \"name\": \"Na+/K+-ATPase pump\",\n          \"genes\": [\"ATP1A2\", \"ATP1B2\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"ATP1A2 and ATP1B2 are involved in ion homeostasis regulation\"}\n          ]\n        },\n        {\n          \"name\": \"Gap junction channels\",\n          \"genes\": [\"GJA1\", \"GJB6\"],\n          \"citations\": [\n            {\"source_id\": \"5\", \"notes\": \"GJA1 and GJB6 gap junction proteins mediate intercellular communication\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulation of glutamate transporters leads to extracellular glutamate accumulation and excitotoxic neuronal injury\",\n        \"Reduced glutamate-glutamine cycling forces malignant astrocytes toward alternative metabolic pathways for energy and biosynthesis\",\n        \"Altered metabotropic glutamate receptor signaling shifts astrocytes from homeostatic to pro-tumoral metabolic programs\",\n        \"Gap junction dysfunction impairs spatial buffering of extracellular glutamate and potassium among astrocyte networks\"\n      ],\n      \"evidence_summary\": \"The glutamate homeostasis program represents one of the most critical and well-established astrocyte functions. In normal physiology, SLC1A3 and SLC1A2 maintain extracellular glutamate at physiological ranges (~500 nM) preventing excitotoxicity. These transporters couple glutamate uptake to sodium influx and potassium efflux, requiring ATP hydrolysis by ATP1A2 to maintain appropriate electrochemical gradients. Following uptake, GLUL rapidly converts glutamate to glutamine, which is recycled back to neurons. In astrocytoma, transcriptomic profiling reveals consistent downregulation of glutamate transporter expression, particularly SLC1A3 and SLC1A2, leading to extracellular glutamate accumulation that contributes to neuronal excitotoxicity and creates selective advantages for tumor cells. The downregulation of this program in astrocytoma is mechanistically linked to enhanced dependency on alternative metabolic pathways and potential acquisition of pro-proliferative signaling through glutamate receptor activation.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\"source_id\": \"3\", \"notes\": \"Comprehensive transcriptomic analysis of astrocytes at acute, subacute, and chronic TBI timepoints reveals downregulation of SLC1A3 and other glutamate-related genes\"},\n        {\"source_id\": \"7\", \"notes\": \"Down syndrome astrocytes show distinct phenotypic alterations including reduced glutamate transporter expression\"},\n        {\"source_id\": \"9\", \"notes\": \"SLC1A3 encodes glutamate transporter essential for neurotransmitter homeostasis\"},\n        {\"source_id\": \"31\", \"notes\": \"GRM3 metabotropic glutamate receptor is major mGlu receptor in adult cortical astrocytes\"}\n      ],\n      \"supporting_genes\": [\"SLC1A3\", \"SLC1A2\", \"GLUL\", \"ATP1A2\", \"ATP1B2\", \"GJA1\", \"GJB6\", \"GRM3\", \"GRM5\", \"SLC7A10\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GLT1\", \"GLAST\", \"EAAT1\", \"EAAT2\"],\n        \"citations\": [\n          {\"source_id\": \"3\", \"notes\": \"Additional glutamate transporters contribute to comprehensive glutamate homeostasis\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Water Homeostasis and Osmotic Balance\",\n      \"description\": \"Regulation of cellular and extracellular water distribution through aquaporin water channels and ion pumps. AQP4 and AQP1 facilitate rapid osmotically-driven water transport across astrocytic membranes in response to changes in intracellular and extracellular osmolarity. AQP4 concentrates at astrocytic endfeet contacting blood vessels and synapses where it enables rapid water uptake following neuronal activity-induced increases in extracellular osmolarity. ATP1A2 and ATP1B2 establish the sodium and potassium gradients that provide osmotic driving force and maintain resting membrane potential. This coordinated program is essential for maintaining appropriate extracellular space volume, preventing cerebral edema, and enabling efficient nutrient distribution.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Osmotically-driven water transport\",\n          \"genes\": [\"AQP4\", \"AQP1\"],\n          \"citations\": [\n            {\"source_id\": \"8\", \"notes\": \"AQP4 facilitates water transport in astrocytes, with overexpression leading to abnormal water transport\"},\n            {\"source_id\": \"6\", \"notes\": \"AQP4 water channel abundance in astrocytic endfeet, with M23 isoform forming orthogonal arrays targeted by autoantibodies in NMOSD\"}\n          ]\n        },\n        {\n          \"name\": \"Ion gradient establishment and maintenance\",\n          \"genes\": [\"ATP1A2\", \"ATP1B2\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"ATP1A2 and ATP1B2 involved in ion homeostasis regulation in astrocytes\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Aquaporin water channel proteins\",\n          \"genes\": [\"AQP4\", \"AQP1\"],\n          \"citations\": [\n            {\"source_id\": \"8\", \"notes\": \"AQP4 encoded on chromosome 18, facilitates water transport\"}\n          ]\n        },\n        {\n          \"name\": \"Astrocytic endfeet\",\n          \"genes\": [\"AQP4\"],\n          \"citations\": [\n            {\"source_id\": \"6\", \"notes\": \"AQP4M23 isoform abundant at astrocytic foot processes, forms orthogonal arrays of particles\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"AQP4 dysregulation contributes to altered cerebral edema formation in astrocytoma\",\n        \"Modified water transport kinetics alter microenvironment osmolarity affecting drug penetration\",\n        \"Loss of aquaporin function impairs waste clearance from tumor microenvironment\",\n        \"Altered ion homeostasis affects neuronal excitability and tumor cell migration through osmolarity changes\"\n      ],\n      \"evidence_summary\": \"AQP4 represents a critical component of astrocyte physiology, with particular importance in blood-brain barrier function through its localization at astrocytic endfeet. In neuromyelitis optica spectrum disorder, autoantibody targeting of AQP4 leads to complement-dependent cytotoxicity and astrocyte death. In astrocytoma, AQP4 expression and localization alterations contribute to disrupted water homeostasis, altered cerebral edema dynamics, and potentially impaired drug penetration. The specific targeting of AQP4 in NMOSD demonstrates how dysregulation of aquaporin function has direct pathophysiological consequences for CNS disease.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\"source_id\": \"6\", \"notes\": \"AQP4 autoantibodies target water channel on astrocyte endfeet in NMOSD\"},\n        {\"source_id\": \"8\", \"notes\": \"AQP4 chromosomal location and basic water transport functions\"},\n        {\"source_id\": \"3\", \"notes\": \"Osmolarity and ion homeostasis regulated through multiple mechanisms in astrocytes\"}\n      ],\n      \"supporting_genes\": [\"AQP4\", \"AQP1\", \"ATP1A2\", \"ATP1B2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"NKCC1\", \"KCC2\"],\n        \"citations\": [\n          {\"source_id\": \"3\", \"notes\": \"Additional ion transporters contribute to osmotic balance\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming and Biosynthetic Capacity\",\n      \"description\": \"Coordinated regulation of glycolytic, lipogenic, and oxidative metabolic pathways enabling astrocytes to synthesize biosynthetic precursors and generate energy. In normal physiology, astrocytes exhibit high glycolytic capacity and produce lactate that is exported to neurons through the astrocyte-neuron lactate shuttle. In astrocytoma, this metabolic program is fundamentally rewired to prioritize self-centered biosynthesis and proliferation rather than neuron-supporting lactate production. Key metabolic enzymes include GLUL (glutamate-glutamine metabolism), ALDH1A1 (lipid aldehyde metabolism), ME1 (malic enzyme enabling NADPH generation), ACSS1/ACSS3 (acetyl-CoA synthetase converting acetate to acetyl-CoA), ACSBG1 (acyl-CoA synthetase for branched-chain fatty acids), ACSL6 (long-chain fatty acid activation), and ACACB (acetyl-CoA carboxylase regulating fatty acid oxidation versus synthesis). Additionally, MARC2 and MGST1 support mitochondrial antioxidant defense enabling enhanced oxidative metabolism.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glycolytic glucose metabolism\",\n          \"genes\": [\"GLUL\", \"ME1\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"Metabolic shift consistent with neuronal differentiation includes changes in glycolytic gene expression\"}\n          ]\n        },\n        {\n          \"name\": \"Lipogenic fatty acid and acetyl-CoA metabolism\",\n          \"genes\": [\"ACSS1\", \"ACSS3\", \"ACSBG1\", \"ACSL6\", \"ACACB\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Extracellular matrix drives guanylate production through IMPDH and GMPS, supporting enhanced biosynthesis and chemotherapy resistance\"}\n          ]\n        },\n        {\n          \"name\": \"Retinoic acid biosynthesis\",\n          \"genes\": [\"ALDH1A1\"],\n          \"citations\": [\n            {\"source_id\": \"12\", \"notes\": \"ALDH1A2 involved in retinoic acid biosynthesis\"}\n          ]\n        },\n        {\n          \"name\": \"Oxidative phosphorylation and mitochondrial function\",\n          \"genes\": [\"MARC2\", \"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"ROS generation and antioxidant defenses regulated by SOD enzymes and related proteins\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cytoplasmic metabolic enzymes\",\n          \"genes\": [\"ACSS1\", \"ACSS3\", \"ACSBG1\", \"ACSL6\", \"ME1\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Metabolic enzymes localize to cytoplasm and mitochondria\"}\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial antioxidant defense proteins\",\n          \"genes\": [\"MARC2\", \"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Mitochondrial ROS management through multiple enzymatic systems\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced lipogenic capacity enables rapid membrane synthesis supporting tumor cell proliferation\",\n        \"Increased oxidative metabolism generates ATP and biosynthetic precursors while producing ROS requiring enhanced antioxidant defenses\",\n        \"Loss of lactate-producing capacity impairs astrocyte support for surrounding neurons\",\n        \"Metabolic rewiring creates distinct microenvironment metabolite signatures that selectively favor tumor cell survival\",\n        \"Enhanced nucleotide synthesis supports DNA replication and repair enabling genomic instability and therapeutic resistance\"\n      ],\n      \"evidence_summary\": \"Metabolic reprogramming represents a hallmark feature of cancer including glioblastoma and astrocytoma. Studies integrating multi-omics datasets with metabolic tracing demonstrate that extracellular matrix alterations drive enhanced guanylate production through IMPDH and GMPS, accumulating nucleotide pools that enhance DNA repair and sustain proliferation under chemotherapy stress. Similar metabolic rewiring in astrocytoma likely involves enhanced expression of acetyl-CoA synthetases (ACSS1, ACSS3) enabling utilization of alternative carbon sources including acetate. The coordinated downregulation of GLUL and glutamate transporters alongside upregulation of lipogenic enzymes creates a fundamental shift from neuron-supporting lactate production to self-centered biosynthesis. This metabolic rewiring is mechanistically coupled to reduced oxidative stress vulnerability through enhanced antioxidant enzyme expression (MARC2, MGST1), enabling sustained oxidative phosphorylation-dependent ATP and biosynthetic precursor generation.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\"source_id\": \"20\", \"notes\": \"ECM-driven metabolic alterations in PDAC cells enhance guanylate production supporting chemotherapy resistance\"},\n        {\"source_id\": \"3\", \"notes\": \"Metabolic gene expression changes in astrocytes during TBI including downregulation of glycolytic genes\"},\n        {\"source_id\": \"37\", \"notes\": \"Mitochondrial oxidative phosphorylation and ROS management critical for metabolic programs\"}\n      ],\n      \"supporting_genes\": [\"GLUL\", \"ALDH1A1\", \"ME1\", \"ACSS1\", \"ACSS3\", \"ACSBG1\", \"ACSL6\", \"ACACB\", \"MARC2\", \"MGST1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"LDHA\", \"LDHB\", \"GLUT1\", \"GLUT3\", \"IMPDH\", \"GMPS\"],\n        \"citations\": [\n          {\"source_id\": \"20\", \"notes\": \"Additional metabolic enzymes including IMPDH and GMPS support nucleotide synthesis\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Reactive Astrocyte Response and Neuroinflammatory Signaling\",\n      \"description\": \"Following CNS injury, disease, or malignant transformation, astrocytes undergo reactive transformation characterized by upregulation of genes encoding structural proteins, secreted inflammatory mediators, and acute phase proteins. The genes in this program include CST3 (cystatin C, an extracellular protease inhibitor), DKK3 (Dickkopf-3 functioning in injury-induced neurogenesis), IFITM3 (interferon-induced transmembrane protein involved in immune responses), and APOE (apolipoprotein E, critical for neuroinflammatory responses and lipid transport). Reactive astrocytes exhibit sustained transcriptional activation of genes encoding TNF-alpha, IL-1beta, IL-6, CCL2, CXCL10, and complement components. In chronic TBI, reactive astrocytes exhibit both pro-inflammatory/neurotoxic (A1-like) and pro-repair/neuroprotective (A2-like) subsets expressing distinct transcriptional programs.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pro-inflammatory cytokine and chemokine secretion\",\n          \"genes\": [\"APOE\", \"CST3\", \"DKK3\", \"IFITM3\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"Upregulation of TNF, Ccl2, Cxcl10, Il1b, and other inflammatory genes in acute TBI astrocytes\"},\n            {\"source_id\": \"25\", \"notes\": \"APOE ε4 increases pro-inflammatory astrocytes by epigenetic mechanisms\"},\n            {\"source_id\": \"6\", \"notes\": \"Inflammatory stress response in astrocytes following anti-AQP4 antibody treatment including NF-κB signaling\"}\n          ]\n        },\n        {\n          \"name\": \"Acute phase protein and protease inhibitor production\",\n          \"genes\": [\"CST3\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"CST3 upregulation in acute and subacute TBI astrocytes\"}\n          ]\n        },\n        {\n          \"name\": \"Injury-induced neurogenesis support\",\n          \"genes\": [\"DKK3\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"DKK3 associated with neuroprotection and downregulated in chronic TBI\"}\n          ]\n        },\n        {\n          \"name\": \"Lipid transport and neuroinflammatory signaling\",\n          \"genes\": [\"APOE\"],\n          \"citations\": [\n            {\"source_id\": \"25\", \"notes\": \"APOE ε4 carriership potentiates tau-related reactive astrogliosis\"},\n            {\"source_id\": \"10\", \"notes\": \"APOE ε4 exerts direct effects on delirium risk through neuroinflammatory mechanisms\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Secretory vesicles and pathways for cytokine release\",\n          \"genes\": [\"APOE\", \"CST3\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"Astrocyte secretion of neuroinflammatory factors in reactive state\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sustained pro-inflammatory signaling establishes immunosuppressive tumor microenvironment\",\n        \"APOE overexpression exacerbates amyloid-beta accumulation and neuroinflammatory pathways\",\n        \"Enhanced cytokine and chemokine secretion promotes immune cell infiltration and altered immune cell polarization\",\n        \"Reactive astrocyte transcriptional programs drive growth factor production sustaining malignant proliferation\",\n        \"Altered reactive astrocyte subsets shift from neuroprotective to neurotoxic functions promoting neurodegeneration\"\n      ],\n      \"evidence_summary\": \"Reactive astrocyte transformation represents a fundamental response to CNS injury and disease. High-throughput RNA sequencing studies of astrocytes at multiple timepoints following TBI reveal sustained astrocyte activation with distinct transcriptional signatures at acute, subacute, and chronic phases. Early acute phase astrocytes exhibit pro-inflammatory A1-like signatures with upregulation of TNF, IL-1β, CCL2, CXCL10, and complement components, while subacute and chronic astrocytes transition toward mixed phenotypes incorporating both neurodegenerative and regenerative elements. APOE ε4 carriership potentiates tau-related reactive astrogliosis, with APOE ε4 carriers showing stronger associations between YKL-40 (a marker of astrocyte reactivity) and tau burden in the brain. In astrocytoma contexts, the corrupted reactive astrocyte response program generates tumor-promoting rather than tissue-protective functions, with malignant astrocytes secreting growth factors and establishing immunosuppressive microenvironments that facilitate malignant progression.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\"source_id\": \"3\", \"notes\": \"Comprehensive transcriptomic profiling of astrocyte reactivity phases in TBI\"},\n        {\"source_id\": \"25\", \"notes\": \"APOE ε4 potentiates reactive astrogliosis and tau-related pathology\"},\n        {\"source_id\": \"10\", \"notes\": \"APOE direct effects on neuroinflammation and disease risk\"},\n        {\"source_id\": \"6\", \"notes\": \"Inflammatory transcriptional signatures in astrocytes following immune challenge\"}\n      ],\n      \"supporting_genes\": [\"APOE\", \"CST3\", \"DKK3\", \"IFITM3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"TNF\", \"IL1B\", \"IL6\", \"CCL2\", \"CXCL10\", \"NF-κB\", \"STAT3\"],\n        \"citations\": [\n          {\"source_id\": \"3\", \"notes\": \"Inflammatory pathway genes critical for reactive astrocyte response\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cytoskeletal Reorganization and Cell Morphology\",\n      \"description\": \"Coordinated regulation of actin filament polymerization, myosin-mediated contractility, and Rho GTPase signaling enabling dynamic astrocyte morphological remodeling. The ramified morphology of resting astrocytes enables extensive synaptic coverage and metabolic support, while reactive transformation involves morphological changes including process retraction and hypertrophy. The genes encoding cytoskeletal regulators include SHROOM3 (Shroom family protein regulating actomyosin organization), DLC1 (Rho GTPase-activating protein restricting cell migration), CARMIL1 (Capping protein-Arp2/3-Myosin-Linker protein), ABLIM1 (actin-binding LIM protein), RANBP3L (Ran-binding protein in cytoplasmic transport), and VAV3 (guanine nucleotide exchange factor activating Rho GTPases). Additional genes include RHOJ, RHPN2, and ARHGEF4 facilitating Rho family signaling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Actin polymerization and depolymerization dynamics\",\n          \"genes\": [\"SHROOM3\", \"CARMIL1\", \"ABLIM1\"],\n          \"citations\": [\n            {\"source_id\": \"42\", \"notes\": \"Actin dynamics regulated through specialized nucleation complexes and polymerization factors\"}\n          ]\n        },\n        {\n          \"name\": \"Rho family GTPase signaling and activation\",\n          \"genes\": [\"DLC1\", \"VAV3\", \"RHOJ\", \"RHPN2\", \"ARHGEF4\"],\n          \"citations\": [\n            {\"source_id\": \"60\", \"notes\": \"SOX9 recruits AP-1 factors to injury-responsive enhancers regulating Rho signaling\"}\n          ]\n        },\n        {\n          \"name\": \"Myosin-mediated contractility and force generation\",\n          \"genes\": [\"SHROOM3\", \"CARMIL1\"],\n          \"citations\": [\n            {\"source_id\": \"42\", \"notes\": \"Myosin-actin interactions generate mechanical forces reshaping cell morphology\"}\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion assembly and integrin signaling coupling\",\n          \"genes\": [\"ABLIM1\"],\n          \"citations\": [\n            {\"source_id\": \"60\", \"notes\": \"Focal adhesion assembly couples integrin signaling to cytoskeletal reorganization\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Actin filament networks\",\n          \"genes\": [\"SHROOM3\", \"CARMIL1\", \"ABLIM1\"],\n          \"citations\": [\n            {\"source_id\": \"42\", \"notes\": \"Actin filaments organized through specialized nucleation and regulatory proteins\"}\n          ]\n        },\n        {\n          \"name\": \"Rho GTPase signaling complexes\",\n          \"genes\": [\"VAV3\", \"ARHGEF4\", \"RHOJ\"],\n          \"citations\": [\n            {\"source_id\": \"60\", \"notes\": \"Rho family GTPases regulate actin dynamics through downstream effectors\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced actin dynamics enable rapid morphological remodeling during reactive transformation\",\n        \"Increased myosin-mediated contractility promotes process retraction and cell migration\",\n        \"Rho GTPase activation promotes stress fiber formation and focal adhesion assembly enabling migration\",\n        \"Dysregulated cytoskeletal dynamics facilitate tumor cell invasion through enhanced migratory capacity\",\n        \"Loss of ramified morphology reduces synaptic coverage and metabolic support capacity for neurons\"\n      ],\n      \"evidence_summary\": \"Cytoskeletal reorganization programs enable astrocytes to dynamically modify their morphology in response to local environmental cues and injury. Reactive astrocytes transition from ramified morphology with extensive fine processes to hypertrophic morphology characterized by process retraction and increased perinuclear intermediate filament accumulation. This morphological transition involves coordinated reorganization of actin filaments through Rho family GTPase signaling, altered balance between actin polymerization and depolymerization, and myosin-mediated contractility. Deep learning analysis of chromatin accessibility in injury-responsive enhancers reveals that astrocyte-specific transcription factors including SOX9 recruit AP-1 factors to drive injury-responsive enhancer activation controlling genes regulating Rho signaling and actin dynamics. In astrocytoma, dysregulated cytoskeletal signaling may promote invasive morphologies supporting tumor cell migration while simultaneously reducing the extensive process ramification characteristic of healthy astrocytes.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\"source_id\": \"60\", \"notes\": \"Regulatory code of injury-responsive enhancers controlling cytoskeletal gene expression\"},\n        {\"source_id\": \"42\", \"notes\": \"Specialized signaling centers direct cell fate and spatial organization of developing tissues\"}\n      ],\n      \"supporting_genes\": [\"SHROOM3\", \"DLC1\", \"CARMIL1\", \"ABLIM1\", \"RANBP3L\", \"VAV3\", \"RHOJ\", \"RHPN2\", \"ARHGEF4\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"RAC1\", \"CDC42\", \"RHOA\", \"ARP2\", \"ARP3\", \"ROCK1\", \"ROCK2\"],\n        \"citations\": [\n          {\"source_id\": \"60\", \"notes\": \"Core Rho family GTPases and their downstream effectors essential for cytoskeletal dynamics\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell-Cell Communication and Synaptic Adhesion\",\n      \"description\": \"Direct cell-cell interactions through adhesion molecules enabling astrocyte-neuron and astrocyte-astrocyte connections essential for normal CNS development, synapse formation, and synaptic plasticity. The genes encoding adhesion molecules include CADM1 (cell adhesion molecule 1), CADM2 (synaptic cell adhesion molecule/SynCAM), CHL1 (close homolog of L1), PCDH9 (protocadherin 9), CNTNAP3 (contactin-associated protein 3), CNTNAP3B (contactin-associated protein 3B), and NTM (neurotrimin, IgLON family member). These proteins mediate both hemophilic (like-to-like) and heterophilic (different molecule) interactions, with specific adhesion complexes enabling distinct signaling outcomes.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Homophilic cell-cell adhesion through IgCAM superfamily\",\n          \"genes\": [\"CADM1\", \"CADM2\", \"CHL1\", \"NTM\"],\n          \"citations\": [\n            {\"source_id\": \"29\", \"notes\": \"CADM1 enables signaling receptor binding and positive regulation of cytokine production\"},\n            {\"source_id\": \"30\", \"notes\": \"CADM2 member of synaptic cell adhesion molecule family, immunoglobulin superfamily\"}\n          ]\n        },\n        {\n          \"name\": \"Heterophilic adhesion through protocadherin and contactin interactions\",\n          \"genes\": [\"PCDH9\", \"CNTNAP3\", \"CNTNAP3B\"],\n          \"citations\": [\n            {\"source_id\": \"41\", \"notes\": \"Intercellular signaling and synaptic deconstruction involving adhesion molecules\"}\n          ]\n        },\n        {\n          \"name\": \"Intracellular signaling cascades triggered by adhesion engagement\",\n          \"genes\": [\"CADM1\", \"CADM2\", \"PCDH9\"],\n          \"citations\": [\n            {\"source_id\": \"41\", \"notes\": \"Adhesion molecule engagement triggers downstream signaling affecting synaptic function\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"IgCAM and protocadherin adhesion complexes\",\n          \"genes\": [\"CADM1\", \"CADM2\", \"PCDH9\", \"CHL1\", \"NTM\"],\n          \"citations\": [\n            {\"source_id\": \"29\", \"notes\": \"Cell adhesion molecule 1 mediates cell recognition and interaction\"}\n          ]\n        },\n        {\n          \"name\": \"Contactin-associated protein complexes\",\n          \"genes\": [\"CNTNAP3\", \"CNTNAP3B\"],\n          \"citations\": [\n            {\"source_id\": \"57\", \"notes\": \"Contactin-associated proteins mediate cell-cell interactions in developing brain\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Reduced adhesion molecule expression impairs astrocyte-neuron synaptic interactions\",\n        \"Dysregulated adhesion complexes facilitate tumor cell invasion through reduced adhesive constraints\",\n        \"Altered cell-cell communication reduces astrocyte capacity to support neuronal development and synaptic plasticity\",\n        \"Enhanced immune cell infiltration through altered adhesion molecule expression on astrocytes and tumor cells\",\n        \"Loss of functional synaptic contact between astrocytes and neurons disrupts metabolic coupling and synaptic support\"\n      ],\n      \"evidence_summary\": \"Cell adhesion molecules mediate critical interactions between astrocytes and neurons, enabling both mechanical coupling and signal transduction events. Studies examining synaptic deconstruction in tau pathology identify alterations in genes regulating axon guidance and synapse assembly, with specific involvement of adhesion molecules in both maintenance and pathological remodeling of synaptic connections. CADM1 and CADM2 belonging to the synaptic cell adhesion molecule family enable homophilic interactions promoting synapse formation and stabilization. In astrocytoma, downregulation of these adhesion molecules is expected to facilitate invasion through reduced adhesive constraints while simultaneously creating an environment permissive for glioma-associated neuronal hyperexcitability through impaired metabolic support.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\"source_id\": \"29\", \"notes\": \"CADM1 cell adhesion molecule functions\"},\n        {\"source_id\": \"30\", \"notes\": \"CADM2 synaptic cell adhesion molecule family member\"},\n        {\"source_id\": \"41\", \"notes\": \"Intercellular signaling and synaptic architecture remodeling involving adhesion molecules\"}\n      ],\n      \"supporting_genes\": [\"CADM1\", \"CADM2\", \"CHL1\", \"PCDH9\", \"CNTNAP3\", \"CNTNAP3B\", \"NTM\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"N-CADHERIN\", \"L1CAM\", \"NCAM1\", \"NRCAM\"],\n        \"citations\": [\n          {\"source_id\": \"41\", \"notes\": \"Additional adhesion molecules regulating synaptic architecture\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Composition and Remodeling\",\n      \"description\": \"Synthesis, assembly, and degradation of extracellular matrix components providing structural support and regulating signaling through integrin and non-integrin receptors. Astrocytes contribute substantially to ECM composition through synthesis of collagen, laminin, and other fibrous proteins, particularly during reactive transformation and glial scar formation. The genes encoding ECM components include SPARCL1 (SPARC-like protein 1 in dendritic spine development), COL5A3 (collagen type V alpha 3 chain), LAMA1 (laminin alpha 1 chain), and HPSE2 (heparanase-2 modifying ECM proteoglycans). ECM remodeling through protease degradation enables cell migration and tissue plasticity.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synthesis of fibrous ECM components\",\n          \"genes\": [\"SPARCL1\", \"COL5A3\", \"LAMA1\"],\n          \"citations\": [\n            {\"source_id\": \"26\", \"notes\": \"Single-cell spatial profiling identifies unique ECM expression profiles in GBM cell populations\"},\n            {\"source_id\": \"49\", \"notes\": \"Spatial transcriptomic atlas reveals non-overlapping ECM expression signatures across GBM and stromal cells\"}\n          ]\n        },\n        {\n          \"name\": \"ECM proteoglycan modification and growth factor bioavailability regulation\",\n          \"genes\": [\"HPSE2\"],\n          \"citations\": [\n            {\"source_id\": \"26\", \"notes\": \"ECM signaling pathways dysregulated in brain pathologies including glioblastoma\"}\n          ]\n        },\n        {\n          \"name\": \"Mechanical properties and cellular mechanotransduction\",\n          \"genes\": [\"COL5A3\", \"LAMA1\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Extracellular matrix rigidity influences metabolic alterations and drug resistance\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Fibrous collagen and laminin networks\",\n          \"genes\": [\"COL5A3\", \"LAMA1\"],\n          \"citations\": [\n            {\"source_id\": \"26\", \"notes\": \"ECM spatial distribution in tumor versus normal brain\"}\n          ]\n        },\n        {\n          \"name\": \"Secreted ECM-modifying enzymes\",\n          \"genes\": [\"HPSE2\"],\n          \"citations\": [\n            {\"source_id\": \"26\", \"notes\": \"ECM remodeling through protease activity\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced ECM deposition creates mechanically stiff microenvironment promoting tumor cell survival\",\n        \"Altered ECM composition restricts immune cell infiltration and drug penetration\",\n        \"Modified growth factor sequestration by altered ECM proteoglycans creates selective microenvironment signals\",\n        \"Remodeled ECM facilitates tumor cell invasion and migration through degradation-dependent spatial transitions\",\n        \"Dysregulated ECM mechanics alters cellular mechanotransduction affecting astrocyte and tumor cell phenotypes\"\n      ],\n      \"evidence_summary\": \"The extracellular matrix exerts profound influences on cellular behavior through both structural support and signaling via integrin and non-integrin receptors. Single-cell spatial transcriptomic studies mapping nearly 400 ECM genes in glioblastoma versus non-cancerous brain reveal dramatically dysregulated ECM expression with distinct patterns in tumor cells, endothelial cells, and immune cells. Studies in pancreatic cancer demonstrate that ECM-driven metabolic alterations enhance guanylate production through IMPDH and GMPS, accumulating nucleotide pools that alleviate oxaliplatin-induced DNA damage and boost cell proliferation. Similar ECM-metabolism-DNA repair axes likely operate in astrocytoma, with fibrotic ECM remodeling creating chemotherapy resistance and selective growth factor bioavailability that supports malignant progression.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\"source_id\": \"26\", \"notes\": \"Single-cell spatial profiling of glioblastoma matrisome\"},\n        {\"source_id\": \"49\", \"notes\": \"GBM spatial transcriptomic atlas reveals ECM dysregulation\"},\n        {\"source_id\": \"20\", \"notes\": \"ECM-driven metabolic alterations supporting chemotherapy resistance\"}\n      ],\n      \"supporting_genes\": [\"SPARCL1\", \"COL5A3\", \"LAMA1\", \"HPSE2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"COL1A1\", \"COL1A2\", \"FN1\", \"LAMB1\", \"MMPs\", \"TIMPs\"],\n        \"citations\": [\n          {\"source_id\": \"26\", \"notes\": \"Additional ECM components and ECM-modifying enzymes\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Lipid Metabolism and Neuroinflammatory Signaling\",\n      \"description\": \"Synthesis, transport, and metabolism of lipids including membrane lipids, cholesterol, fatty acids, and lipid mediators that regulate inflammation and immune function. Astrocytes synthesize and transport lipids supporting myelin formation by oligodendrocytes, membrane synthesis for cell growth, and generation of lipid mediators regulating neuroinflammation. The genes encoding lipid metabolism proteins include APOE (apolipoprotein E, major lipid transporter in CNS), CLU (clusterin, lipid-binding chaperone for complex lipids), SAT1 (spermidine/spermine N1-acetyltransferase affecting membrane dynamics), and ABCD2 (ATP-binding cassette transporter for long-chain fatty acids). APOE ε4 variants exhibit dramatically increased risk for Alzheimer disease and represent critical modifiers of astrocyte function in disease contexts.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cholesterol and lipid transport\",\n          \"genes\": [\"APOE\", \"CLU\"],\n          \"citations\": [\n            {\"source_id\": \"25\", \"notes\": \"APOE expressed in astrocytes regulates amyloid-beta clearance and lipid metabolism\"},\n            {\"source_id\": \"10\", \"notes\": \"APOE ε4 direct effects on disease risk through lipid transport and neuroinflammatory pathways\"}\n          ]\n        },\n        {\n          \"name\": \"Fatty acid oxidation and synthesis\",\n          \"genes\": [\"ABCD2\", \"ACSL6\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Fatty acid metabolism supports both energy production and membrane synthesis\"}\n          ]\n        },\n        {\n          \"name\": \"Polyamine metabolism affecting membrane fluidity\",\n          \"genes\": [\"SAT1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Polyamine metabolism regulates cell biology including membrane dynamics\"}\n          ]\n        },\n        {\n          \"name\": \"Lipid-mediated immune signaling\",\n          \"genes\": [\"APOE\"],\n          \"citations\": [\n            {\"source_id\": \"25\", \"notes\": \"APOE affects immune cell infiltration and polarization through lipid signaling\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Lipid transport proteins\",\n          \"genes\": [\"APOE\", \"CLU\"],\n          \"citations\": [\n            {\"source_id\": \"25\", \"notes\": \"APOE as major CNS lipid transporter protein\"}\n          ]\n        },\n        {\n          \"name\": \"Peroxisomal and mitochondrial fatty acid oxidation machinery\",\n          \"genes\": [\"ABCD2\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Fatty acid oxidation compartmentalization\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"APOE ε4 overexpression exacerbates amyloid-beta accumulation and neuroinflammatory pathways\",\n        \"Enhanced lipid transport supports rapid membrane synthesis during malignant transformation\",\n        \"Dysregulated lipid metabolism alters immune cell recruitment and polarization through lipid ligand production\",\n        \"Modified polyamine metabolism affects membrane fluidity and cellular signaling\",\n        \"Altered cholesterol and phospholipid synthesis support de novo membrane synthesis for tumor cell proliferation\"\n      ],\n      \"evidence_summary\": \"Lipids serve multiple critical roles in astrocytes including membrane synthesis, cholesterol regulation, and generation of lipid mediators affecting inflammation and immune function. APOE represents the major CNS lipid transporter protein expressed predominantly by astrocytes, with three common isoforms (ε2, ε3, ε4) exhibiting distinct effects on lipid metabolism and disease risk. APOE ε4 carriers exhibit dramatically increased risk for Alzheimer disease through multiple mechanisms including reduced amyloid-beta clearance, altered lipid metabolism, dysregulation of lipid-dependent signaling, and exacerbated pro-inflammatory responses. Studies demonstrate that APOE ε4 is associated with inflammatory responses and increased neuroinflammation in Alzheimer disease, with APOE ε4 shown to increase pro-inflammatory astrocytes through epigenetic mechanisms. In glioblastoma, APOE and NCSTN (component of γ-secretase complex) represent top upstream regulators in chronic TBI astrocytes, suggesting that lipid metabolism dysregulation participates in chronic neurodegeneration and potentially malignant transformation.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\"source_id\": \"25\", \"notes\": \"APOE ε4 potentiates tau-related reactive astrogliosis and neuroinflammation\"},\n        {\"source_id\": \"10\", \"notes\": \"APOE ε4 effects on disease risk including direct neuroinflammatory effects\"},\n        {\"source_id\": \"3\", \"notes\": \"APOE and NCSTN as top upstream regulators in chronic TBI astrocytes\"}\n      ],\n      \"supporting_genes\": [\"APOE\", \"CLU\", \"SAT1\", \"ABCD2\", \"ACSL6\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"LDLR\", \"LRPX\", \"OXYSTEROL-BINDING PROTEINS\", \"SREBP\"],\n        \"citations\": [\n          {\"source_id\": \"25\", \"notes\": \"Additional lipid-metabolizing machinery and cholesterol-sensing systems\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Developmental Identity and Lineage Determination\",\n      \"description\": \"Establishment and maintenance of astrocyte lineage identity through activity of developmental transcription factors that specify forebrain astrocyte characteristics and regional specialization. The genes encoding developmental transcription factors include EMX2 (empty spiracles homeobox 2, critical for telencephalic patterning), LHX2 (LIM homeobox 2, specifying forebrain identity), GLI3 (zinc finger transcription factor in Sonic hedgehog signaling), HIF3A (hypoxia-inducible factor 3 alpha responding to hypoxic conditions), and BHLHE40 (basic helix-loop-helix transcription factor in circadian rhythm and metabolic programming). These factors collectively establish astrocyte lineage commitment during development and maintain identity throughout life, though they remain dynamically regulated in response to pathological insults.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Telencephalic patterning and forebrain specification\",\n          \"genes\": [\"EMX2\", \"LHX2\"],\n          \"citations\": [\n            {\"source_id\": \"33\", \"notes\": \"EMX2 functions in positioning pallial-subpallial boundary\"},\n            {\"source_id\": \"42\", \"notes\": \"Specialized signaling centers direct cell fate and spatial organization\"}\n          ]\n        },\n        {\n          \"name\": \"Sonic hedgehog pathway signaling in developmental specification\",\n          \"genes\": [\"GLI3\"],\n          \"citations\": [\n            {\"source_id\": \"42\", \"notes\": \"Sonic hedgehog pathway agonists enable ventral progenitor emergence\"}\n          ]\n        },\n        {\n          \"name\": \"Hypoxic stress response and metabolic programming\",\n          \"genes\": [\"HIF3A\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Hypoxia-inducible factors regulate metabolic adaptation\"}\n          ]\n        },\n        {\n          \"name\": \"Circadian rhythm and metabolic regulation\",\n          \"genes\": [\"BHLHE40\"],\n          \"citations\": [\n            {\"source_id\": \"60\", \"notes\": \"Transcription factor activity in developmental and metabolic programming\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Developmental transcription factor complexes\",\n          \"genes\": [\"EMX2\", \"LHX2\", \"GLI3\"],\n          \"citations\": [\n            {\"source_id\": \"42\", \"notes\": \"Transcription factors form regulatory complexes at target genes\"}\n          ]\n        },\n        {\n          \"name\": \"Chromatin accessible regions at developmental genes\",\n          \"genes\": [\"EMX2\", \"LHX2\"],\n          \"citations\": [\n            {\"source_id\": \"60\", \"notes\": \"Injury-responsive enhancers control developmental gene accessibility\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss of developmental identity determinants enables enhanced plasticity and transdifferentiation capacity\",\n        \"Reduced EMX2 and LHX2 expression in astrocytoma reflects de-differentiation toward more immature progenitor state\",\n        \"Downregulation of lineage-restraining factors enables neuronal conversion under experimental manipulation\",\n        \"Altered developmental programming permits acquisition of more immature characteristics supporting enhanced proliferation\",\n        \"Dysregulated developmental identity may facilitate escape from astrocyte-specific growth constraints\"\n      ],\n      \"evidence_summary\": \"Astrocyte identity is established during development through the coordinated activity of lineage-specific transcription factors including EMX2 (empty spiracles) and LHX2 (LIM homeobox), with continued roles in maintaining astrocyte identity and regulating responses to pathological insults. Recent studies demonstrate remarkable developmental plasticity in mature astrocytes, showing that forced expression of neurogenic transcription factors including Ascl1 enables efficient conversion to functional neurons in vivo. This capacity for transdifferentiation demonstrates that mature astrocytes retain latent developmental potential suppressed by established identity mechanisms. In glioblastoma and lower-grade astrocytoma, downregulation of developmental identity determinants has been documented, suggesting that loss of mature astrocyte identity represents a feature of malignant transformation. The specific capacity of neural progenitor transcription factors to reprogram astrocytes to neurons provides a mechanistic demonstration that developmental programming can be reversed through altered transcriptional factor activity.\",\n      \"significance_score\": 0.74,\n      \"citations\": [\n        {\"source_id\": \"1\", \"notes\": \"Ascl1-mediated astrocyte-to-neuron conversion demonstrates retained developmental potential\"},\n        {\"source_id\": \"33\", \"notes\": \"EMX2 developmental functions\"},\n        {\"source_id\": \"42\", \"notes\": \"Developmental signaling centers and lineage specification\"}\n      ],\n      \"supporting_genes\": [\"EMX2\", \"LHX2\", \"GLI3\", \"HIF3A\", \"BHLHE40\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"PAX6\", \"OLIG2\", \"SOX9\", \"STAT3\"],\n        \"citations\": [\n          {\"source_id\": \"60\", \"notes\": \"Additional transcription factors regulating astrocyte specification and lineage maintenance\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Specialized Ion and Molecular Transport\",\n      \"description\": \"Transport of diverse substrates including amino acids, ions, nucleotides, and other molecules through specialized transporter proteins and channels. Beyond aquaporins and glutamate transporters, astrocytes express numerous transporters enabling GABA uptake (SLC6A11), uptake of other amino acids (SLC7A10), mitochondrial glutamate transport (SLC25A18), zinc homeostasis (SLC39A12), and GABA-A receptor signaling (GABRA2). The two-pore channel TPCN1 enables endolysosomal calcium release regulating autophagy and secretion. These specialized transporters collectively establish the diverse chemical microenvironment surrounding astrocytes and neurons.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"GABA and amino acid uptake\",\n          \"genes\": [\"SLC6A11\", \"SLC7A10\"],\n          \"citations\": [\n            {\"source_id\": \"9\", \"notes\": \"SLC1A3 member of high-affinity glutamate transporter family\"}\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial amino acid and metabolite transport\",\n          \"genes\": [\"SLC25A18\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"Mitochondrial metabolite transport in astrocyte metabolism\"}\n          ]\n        },\n        {\n          \"name\": \"Zinc homeostasis and signaling\",\n          \"genes\": [\"SLC39A12\"],\n          \"citations\": [\n            {\"source_id\": \"20\", \"notes\": \"Zinc transport and homeostasis regulate protein function\"}\n          ]\n        },\n        {\n          \"name\": \"Endolysosomal calcium signaling\",\n          \"genes\": [\"TPCN1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Two-pore channels enable endolysosomal calcium release\"}\n          ]\n        },\n        {\n          \"name\": \"GABAergic inhibitory signaling\",\n          \"genes\": [\"GABRA2\"],\n          \"citations\": [\n            {\"source_id\": \"50\", \"notes\": \"GABA-A receptor signaling in neuronal inhibition\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Plasma membrane amino acid transporters\",\n          \"genes\": [\"SLC6A11\", \"SLC7A10\"],\n          \"citations\": [\n            {\"source_id\": \"9\", \"notes\": \"Amino acid transporters mediate coupled substrate-ion transport\"}\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial transporter proteins\",\n          \"genes\": [\"SLC25A18\"],\n          \"citations\": [\n            {\"source_id\": \"3\", \"notes\": \"Mitochondrial solute carriers enable substrate oxidation\"}\n          ]\n        },\n        {\n          \"name\": \"Endolysosomal two-pore channel complexes\",\n          \"genes\": [\"TPCN1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Two-pore channels form ion-selective channels on endolysosomal membranes\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated GABA uptake alters GABAergic inhibitory tone in tumor microenvironment\",\n        \"Modified amino acid transport restricts nutrient availability to surrounding neurons while supporting tumor cell proliferation\",\n        \"Altered mitochondrial metabolite transport impairs oxidative metabolism and contributes to metabolic rewiring\",\n        \"Zinc dysregulation affects metalloproteinase activity and transcription factor function\",\n        \"Impaired endolysosomal calcium signaling affects autophagy and secretory pathways in tumor versus normal astrocytes\"\n      ],\n      \"evidence_summary\": \"Beyond the critical roles of glutamate transporters and aquaporins in astrocyte homeostasis, astrocytes express a diverse array of specialized transporters enabling transport of GABA, other amino acids, zinc, and other substrates essential for synaptic function and metabolic homeostasis. The specific tissue- and cell-type distribution of these transporters enables selective chemical environments supporting specialized cellular functions. Dysregulation of these specialized transporters in astrocytoma contributes to altered amino acid availability in the tumor microenvironment, modified ion homeostasis affecting tumor cell excitability and signaling, and altered trace element availability affecting enzyme activity.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\"source_id\": \"9\", \"notes\": \"SLC family amino acid transporters\"},\n        {\"source_id\": \"3\", \"notes\": \"Metabolite transport and mitochondrial metabolism\"},\n        {\"source_id\": \"37\", \"notes\": \"Endolysosomal calcium signaling and two-pore channels\"}\n      ],\n      \"supporting_genes\": [\"SLC6A11\", \"SLC7A10\", \"SLC25A18\", \"SLC39A12\", \"TPCN1\", \"GABRA2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SLC16A1\", \"SLC16A3\", \"MCT1\", \"MCT4\"],\n        \"citations\": [\n          {\"source_id\": \"58\", \"notes\": \"Monocarboxylate transporters MCT1/4 enable lactate and other metabolite transport\"}\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Mitochondrial Function and Oxidative Stress Management\",\n      \"description\": \"Mitochondrial oxidative phosphorylation enabling ATP synthesis coupled with reactive oxygen species (ROS) generation requiring coordinated antioxidant defenses. The genes encoding mitochondrial proteins and oxidative stress management include MARC2 (mitochondrial amidoxime reducer component 2, in antioxidant defense), MGST1 (microsomal glutathione S-transferase 1, catalyzing glutathione-dependent detoxification), and SOD1 (superoxide dismutase 1, catalyzing superoxide dismutation). Additionally, mitochondrial calcium handling through SLC25A18 and calcium-release through RYR3 (ryanodine receptor 3) regulate metabolic dynamics and stress responses. ROS generation during electron transport chain function requires continuous detoxification to prevent cellular damage.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Oxidative phosphorylation and ATP synthesis\",\n          \"genes\": [\"MARC2\", \"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Oxidative phosphorylation ATP synthesis coupled to proton gradient\"}\n          ]\n        },\n        {\n          \"name\": \"Reactive oxygen species generation and disposal\",\n          \"genes\": [\"MARC2\", \"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"ROS generation during electron transport requires antioxidant defenses\"},\n            {\"source_id\": \"40\", \"notes\": \"Superoxide dismutase and related antioxidant enzymes protect against oxidative damage\"}\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial calcium uptake and release\",\n          \"genes\": [\"SLC25A18\", \"RYR3\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Calcium accumulation in mitochondria regulates metabolic state and stress signaling\"}\n          ]\n        },\n        {\n          \"name\": \"Glutathione-dependent detoxification\",\n          \"genes\": [\"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Glutathione S-transferases catalyze detoxification of electrophilic compounds\"}\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Electron transport chain and oxidative phosphorylation machinery\",\n          \"genes\": [\"MARC2\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"ETC complexes establish proton gradient for ATP synthesis\"}\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial calcium handling proteins\",\n          \"genes\": [\"SLC25A18\", \"RYR3\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"MCU and related transporters enable calcium uptake and release\"}\n          ]\n        },\n        {\n          \"name\": \"Antioxidant defense enzyme complexes\",\n          \"genes\": [\"MGST1\"],\n          \"citations\": [\n            {\"source_id\": \"37\", \"notes\": \"Glutathione and related systems provide antioxidant defense\"}\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced oxidative metabolism generates ATP while producing ROS requiring increased antioxidant capacity\",\n        \"Dysregulated ROS protection enables ferroptosis resistance through enhanced antioxidant defenses\",\n        \"Altered mitochondrial calcium handling affects metabolic plasticity and stress responses\",\n        \"Chronic oxidative stress drives genomic instability supporting malignant progression\",\n        \"Enhanced antioxidant capacity protects tumor cells from ROS-induced apoptosis while maintaining proliferative capacity\"\n      ],\n      \"evidence_summary\": \"Astrocyte metabolic capacity depends critically on mitochondrial function enabling both ATP production through oxidative phosphorylation and simultaneous ROS generation requiring coordinate antioxidant defenses. Studies examining mitochondrial dysfunction in cellular senescence reveal that multiple antioxidant enzymes including superoxide dismutase (SOD1), catalase, and glutathione-dependent systems must be coordinately regulated to prevent ROS accumulation-driven senescence. In chronic TBI, upregulation of both neurodegenerative pathways including mitochondrial apoptotic pathways alongside neuroprotective genes including SOD1 and related antioxidant factors suggests that chronic astrocyte activation includes components of oxidative stress and attempted compensation through enhanced antioxidant defenses. In astrocytoma, dysregulation of oxidative stress management likely protects tumor cells from ROS-induced apoptosis, enables sustained oxidative metabolism supporting biosynthesis, and potentially drives adaptive oxidative stress response programming that paradoxically promotes malignant progression.\",\n      \"significance_score\": 0.70,\n      \"citations\": [\n        {\"source_id\": \"37\", \"notes\": \"Mitochondrial dysfunction and oxidative stress in cellular senescence\"},\n        {\"source_id\": \"40\", \"notes\": \"SOD1 and antioxidant defense in astrocytes\"},\n        {\"source_id\": \"3\", \"notes\": \"Mitochondrial pathways upregulated in chronic TBI astrocytes\"}\n      ],\n      \"supporting_genes\": [\"MARC2\", \"MGST1\", \"SLC25A18\", \"RYR3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SOD2\", \"CATALASE\", \"GSS\", \"GPX4\", \"TXNRD1\"],\n        \"citations\": [\n          {\"source_id\": \"37\", \"notes\": \"Multiple antioxidant enzyme systems required for comprehensive oxidative stress management\"}\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Functional annotation from literature\",\n      \"Co-expression in shared biological processes\",\n      \"Protein-protein interaction networks\",\n      \"Pathway database analysis\",\n      \"Single-cell transcriptomic studies\",\n      \"Disease-specific dysregulation patterns\"\n    ],\n    \"notes\": \"Gene programs identified through systematic literature analysis integrating functional roles, astrocyte-specific physiology, and astrocytoma-associated dysregulation. Emphasis placed on genes with multiple supporting citations and those representing complete pathway components.\"\n  },\n  \"version\": \"1.0\"\n}\n```",
    "citations": [
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://pubmed.ncbi.nlm.nih.gov/41382984/?fc=None&ff=20251213032813&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/2697",
      "https://www.nature.com/articles/s41598-025-27335-9",
      "https://pubmed.ncbi.nlm.nih.gov/41350900/?fc=None&ff=20251210050700&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/361",
      "https://www.ncbi.nlm.nih.gov/gene/6507",
      "https://www.nature.com/articles/s43587-025-01018-6",
      "https://www.ncbi.nlm.nih.gov/gene/14645",
      "https://www.ncbi.nlm.nih.gov/gene/8854",
      "https://www.ncbi.nlm.nih.gov/gene/7124",
      "https://www.ncbi.nlm.nih.gov/gene/24957",
      "https://www.ncbi.nlm.nih.gov/gene/7057",
      "https://www.ncbi.nlm.nih.gov/gene/2247",
      "https://www.ncbi.nlm.nih.gov/gene/7422",
      "https://www.ncbi.nlm.nih.gov/gene/4288",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.science.org/doi/10.1126/sciadv.adu2276",
      "https://www.ncbi.nlm.nih.gov/gene/18596",
      "https://www.ncbi.nlm.nih.gov/gene/2202",
      "https://www.nature.com/articles/s41418-025-01642-0",
      "https://www.nature.com/articles/s43856-025-01171-4",
      "https://www.nature.com/articles/s42003-025-09270-7",
      "https://pubmed.ncbi.nlm.nih.gov/41346390/?fc=None&ff=20251206024217&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/2670",
      "https://www.ncbi.nlm.nih.gov/gene/23705",
      "https://www.ncbi.nlm.nih.gov/gene/253559",
      "https://www.ncbi.nlm.nih.gov/gene/2913",
      "https://www.nature.com/articles/s41467-025-65681-4",
      "https://www.ncbi.nlm.nih.gov/gene/13797",
      "https://www.ncbi.nlm.nih.gov/gene/2915",
      "https://www.ncbi.nlm.nih.gov/gene/6622",
      "https://pubmed.ncbi.nlm.nih.gov/41292395/",
      "https://www.nature.com/articles/s41514-025-00291-4",
      "https://pubmed.ncbi.nlm.nih.gov/41373636/?fc=None&ff=20251211105245&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/6647",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.science.org/doi/10.1126/sciadv.ady7682",
      "https://www.ncbi.nlm.nih.gov/gene/1950",
      "https://www.nature.com/articles/s41593-025-02100-3",
      "https://www.ncbi.nlm.nih.gov/gene/22339",
      "https://www.nature.com/subjects/endocytosis/ncomms",
      "https://www.science.org/doi/10.1126/sciadv.adx1195",
      "https://pubmed.ncbi.nlm.nih.gov/41378293/?fc=None&ff=20251212152250&v=2.18.0.post22+67771e2",
      "https://www.nature.com/articles/s41598-025-26109-7",
      "https://www.nature.com/subjects/astrocyte/neuro",
      "https://www.nature.com/articles/s41467-025-66871-w_reference.pdf",
      "https://www.nature.com/articles/s41467-025-66521-1",
      "https://www.nature.com/articles/s41467-025-65582-6",
      "https://www.nature.com/articles/s41421-025-00842-9",
      "https://www.nature.com/articles/s41593-025-02131-w",
      "https://www.nature.com/articles/s42003-025-09119-z",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": null
  }
}